• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    RIFAXIMIN FORMULATIONS AND THEIR USE. The present invention relates to new forms of rifaximin comprising solid dispersions of rifaximin, methods of their production and their use in medicinal preparations and therapeutic methods.
    公开号:BR112013000802B1
    申请号:R112013000802-4
    申请日:2011-07-12
    公开日:2021-08-31
    发明作者:Jon Selbo；Jing Teng；Mohammed A. Kabir；Pam Golden
    申请人:Salix Pharmaceuticals, Ltd.；
    IPC主号:
    专利说明:

    Related Applications
    This application claims the benefit of US Provisional Application No. 61/363,609 filed July 12, 2010, and US Provisional Application No. 61/419,056, filed December 2, 2010, the entire contents of each of which are incorporated herein by reference. Background
    The present invention relates to arifaximin (INN; See The Merck Index, XIII Ed., 8304) which is an antibiotic belonging to the rifamycin class of antibiotics, for example a pyrido-imidazo rifamycin. Rifaximin exerts its broad antibacterial activity, for example, in the gastrointestinal tract against localized gastrointestinal bacteria that cause infectious diarrhea, irritable bowel syndrome, small bowel bacterial overgrowth, Crohn's disease, and pancreatic insufficiency among other diseases. Rifaximin has been reported to be characterized by negligible systemic absorption due to its chemical and physical characteristics (Descombe JJ et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res, 14 (2), 51- 56, (1994)).
    Rifaximin is described in Italian Patent IT 1154655 and EP 0161534, both of which are incorporated herein by reference in their entirety for all purposes. EP 0161534 discloses a process for the production of rifamycin using rifaximin O as the starting material (The Merck Index, XIII Ed., 8301). US Patent No. 7,045,620 B1 and PCT Publication WO 2006/094662 A1 disclose polymorphic forms of rifaximin. There is a need in the art for rifaximin formulations to better treat gastrointestinal and other ailments. summary
    Provided herein are solid dispersion forms of rifaximin with a variety of polymers and polymer concentrations.
    In one aspect, provided herein are solid dispersion forms of rifaximin.
    In one embodiment, the solid form dispersion of rifaximin is characterized by an XRPD substantially similar to one or more of the XRPDs of Figures 2, 7, 12, 17, 22, 31 and 36.
    In one embodiment, the solid form dispersion of rifaximin is characterized by a thermogram substantially similar to Figures 3-6, 8-11, 13-16, 18-21, 23-26, 27-30 and 32.
    In one embodiment, the shape has the appearance of a single glass transition temperature (Tg).
    In one embodiment, a Tg of a form increases with an increased concentration of rifaximin.
    In one embodiment, a form subjected to stress at 70°C/75%RH for one week, the solids are still amorphous to X-ray according to XRPD.
    In one modality, a form subjected to stress at 70°C/75%RH for 3 weeks, the solids are still amorphous to X-ray according to XRPD.
    In one modality, a form subjected to stress at 70°C/75%RH for 6 weeks, the solids are still amorphous on X-ray according to XRPD.
    In one embodiment, a form subjected to stress at 70°C/75%RH for 12 weeks, the solids are still amorphous to X-ray according to XRPD.
    In one aspect provided herein are microgranules comprising one or more of the solid dispersion forms of rifaximin described herein.
    In one embodiment, the microgranules further comprise a polymer.
    In one embodiment, the polymer comprises one or more of polyvinylpyrrolidone (PVP) grade K-90, methylcellulose hydroxypropyl phthalate (HPMC-P) grade 55, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) grades HG and MG, or a polymethacrylate (Eudragit® L100-55).
    In specific embodiments, the microgranules comprise 25 to 75% polymer, 40 to 60% polymer, or 40 to 50% polymer. In an exemplary embodiment, the microgranules comprise 42 to 44% polymer.
    In one embodiment, the microgranules comprise equal amounts of rifaximin and polymer.
    In another embodiment, the microgranules further comprising an intragranular release control agent. In exemplary embodiments, the intragranular release controlling agent comprises a pharmaceutically acceptable excipient, disintegrant, crosprovidone, sodium starch glycolate, corn starch, microcrystalline cellulose, cellulosic derivatives, sodium bicarbonate and sodium alginate.
    In one embodiment, the intragranular release control agent comprises from about 2% by weight to about 40% by weight of the microgranule, from about 5% by weight to about 20% by weight of the microgranule, or around 10% by weight of the microgranule.
    In another embodiment, the intragranular release control agent comprises a pharmaceutically acceptable disintegrant, for example, one selected from the group consisting of crosprovidone, sodium starch glycolate, corn starch, microcrystalline cellulose, cellulose derivatives, sodium bicarbonate and alginate of sodium.
    In another embodiment, the microgranules further comprise a wetting agent or surfactant, for example, a nonionic surfactant.
    In one embodiment, the nonionic surfactant comprises between about 2% by weight to about 10% by weight of the microgranule, between about 4% by weight to about 8% by weight of the microgranule, or about 5, 0% by weight of the microgranule.
    In one embodiment, the nonionic surfactant comprises a poloxamer, eg poloxamer 407, also known as Pluronic F-127.
    In another embodiment, the microgranules further comprise an antioxidant.
    In exemplary modalities, the antioxidant is butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) or propyl gallate (GP).
    In another embodiment, the antioxidant comprises from about 0.1% by weight to about 3% by weight of the microgranule or from about 0.5% by weight to about 1% by weight of the microgranule.
    In another aspect, provided herein are pharmaceutical compositions comprising the microgranules described herein.
    In one embodiment, the pharmaceutical compositions further comprise one or more pharmaceutically acceptable excipients.
    In one embodiment, the pharmaceutical compositions are tablets or capsules.
    In one embodiment, the pharmaceutical compositions comprise a disintegrant.
    In one embodiment, the polymer comprises one or more of polyvinylpyrrolidone (PVP) grade K-90, methylcellulose hydroxypropyl phthalate (HPMC-P) grade 55, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) grades HG and MG, or a polymethacrylate (Eudragit® L100-55).
    In one aspect, provided herein are solid dispersion pharmaceutical formulations comprising: rifaximin, HPMC-AS, in a 50:50 rifaximin to polymer ratio, a nonionic surfactant polyol, and an intragranular release control agent.
    In one embodiment, the intragranular release control agent comprises about 10% by weight of the formulation.
    In one aspect, provided herein are processes for producing a solid dispersion of rifaximin comprising: preparing a slurry of methanol, rifaximin, a polymer and a surfactant; spray drying the slurry; and mixing the spray dried slurry with an intragranular release control agent.
    In one aspect, provided herein are processes for producing a solid dispersion of rifaximin comprising: preparing a slurry of methanol, rifaximin, HPMC-AS MG and Pluronic F-127; spray drying the slurry, and mixing the spray dried slurry with an intragranular release controlling agent.
    In one embodiment, the intragranular release control agent comprises croscarmellose sodium.
    A process for producing the solid form dispersion of 5.
    In one embodiment, pharmaceutical compositions comprising SD rifaximin, a polymer, a surfactant, and a release controlling agent are provided. In one embodiment, pharmaceutical compositions comprising SD rifaximin, HPMC-AS, Pluronic F127, and croscarmellose Na (CS) are provided. In one embodiment, the pharmaceutical compositions are tablets or pills.
    In additional embodiments, the pharmaceutical compositions further comprise fillers, glidants or lubricants.
    In specific embodiments, the pharmaceutical compositions comprise the component ratios shown in Table 37.
    Other modality and aspects are described below. Brief Description of Drawings
    Figure 1. Chemical structure of rifaximin.
    Figure 2. Overlay of XRPD patterns for rifaximin/PVP K-90 dispersions obtained from methanol by spray drying.
    Figure 3. mDSC thermogram for 25:75 (w/w) dispersion of rifaximin/PVP K-90 obtained from methanol by spray drying.
    Figure 4. mDSC thermogram for 50:50 (w/w) dispersion of rifaximin/PVP K-90 obtained from methanol by spray drying.
    Figure 5. mDSC thermogram for 75:25 (w/w) dispersion of rifaximin/PVP K-90 obtained from methanol by spray drying.
    Figure 6. mDSC thermogram overlay of rifaximin/PVP K-90 dispersions obtained from methanol by spray drying.
    Figure 7. Overlay XRPD patterns for rifaximin/HPMC-P dispersions obtained from methanol by spray drying.
    Figure 8. mDSC thermogram for 25:75 (w/w) rifa-ximine/HPMC-P dispersion obtained from methanol by spray drying.
    Figure 9. mDSC thermogram for 50:50 (w/w) rifa-ximine/HPMC-P dispersion obtained from methanol by spray drying.
    Figure 10. mDSC thermogram for 75:25 (w/w) ri-faximin/HPMC-P dispersion obtained from methanol by spray drying.
    Figure 11. MDSC thermogram overlay for rifaximin/HPMC-P dispersions obtained from methanol by spray drying.
    Figure 12. Overlay XRPD patterns for rifaximin/HPMC-AS HG dispersions obtained from methanol by spray drying.
    Figure 13. mDSC thermogram for 25:75 (w/w) ri-faximin/HPMC-AS HG dispersion obtained from methanol by spray drying.
    Figure 14. mDSC thermogram for 50:50 (w/w) rifaximine/HPMC-AS HG dispersion obtained from methanol by spray drying.
    Figure 15. mDSC thermogram for 75:25 (w/w) ri-faximin/HPMC-AS HG dispersion obtained from methanol by spray drying.
    Figure 16. mDSC thermogram overlay for rifaximin/HPMC-AS HG dispersions obtained from methanol by spray drying.
    Figure 17. XRPD pattern overlay for rifaximin/HPMC-AS MG dispersions obtained from methanol by spray drying.
    Figure 18. mDSC thermogram for 25:75 (w/w) rifaximine/HPMC-AS MG dispersion obtained from methanol by spray drying.
    Figure 19. mDSC thermogram for 50:50 (w/w) rifaximine/HPMC-AS MG dispersion obtained from methanol by spray drying.
    Figure 20. mDSC thermogram for 75:25 (w/w) rifaximine/HPMC-AS MG dispersion obtained from methanol by spray drying.
    Figure 21. MDSC thermogram overlay for rifaximin/HPMC-AS MG dispersions obtained from methanol by spray drying.
    Figure 22. XRPD pattern overlay for Rifaximin/Eudragit L100-55 dispersions obtained from methanol by spray drying.
    Figure 23. mDSC thermogram for 25:75 (w/w) ri-faximin/Eudragit L100-55 dispersion obtained from methanol by spray drying.
    Figure 24. mDSC thermogram for 50:50 (w/w) ri-faximin/Eudragit L100-55 dispersion obtained from methanol by spray drying.
    Figure 25. mDSC thermogram for 75:25 (w/w) ri-faximin/Eudragit L100-55 dispersion obtained from methanol by spray drying.
    Figure 26. MDSC thermogram overlay for Rifaximin/Eudragit L100-55 dispersions obtained from methanol by spray drying.
    Figure 27. mDSC thermogram for 25:75 (w/w) rifaximin/HPMC-P dispersion strained at 40°C/75% RH for 7 d.
    Figure 28. mDSC thermogram for 75:25 (w/w) dispersion of ri-faximin/HPMC-AS HG strained at 40°C/75% RH for 7 d.
    Figure 29. mDSC thermogram for 75:25 (w/w) dispersion of ri-faximin/HPMC-AS MG tensioned at 40°C/75% RH for 7 d.
    Figure 30. mDSC thermogram for 25:75 (w/w) dispersion of ri-faximin/Eudragit L100-55 tensioned at 40°C/75% RH for 7 d.
    Figure 31. XRPD pattern for 50:50 (w/w) dispersion of rifaximin/HPMC-AS MG.
    Figure 32. Modular DSC thermograms for 50:50 (w/w) dispersion of rifaximin/HPMC-AS MG.
    Figure 33. TG-IR analysis for 50:50 (w/w) dispersion of rifaximin/HPMC-AS MG - TGA data.
    Figure 34. TG-IR analysis for 50:50 (w/w) dispersion of rifaximin/HPMC-AS MG - Gram-Schmidt plot and cascade plot.
    Figure 35. TG-IR analysis for 50:50 (w/w) dispersion of rifaximin/HPMC-AS MG.
    Figure 36. XRPD pattern for 25:75 (w/w) rifaximin/HPMC-P dispersion.
    Figure 37. Modular DSC thermograms for 25:75 (w/w) rifaximin/HPMC-P dispersion.
    Figure 38. TG-IR analysis for 25:75 (w/w) rifaximin/HPMC-P dispersion - TGA data.
    Figure 39. TG-IR analysis for 25:75 (w/w) dispersion of rifaximin/HPMC-P - Gram-Schmidt plot and cascade plot.
    Figure 40. TG-IR analysis for 25:75 (w/w) rifaximin/HPMC-P dispersion.
    Figure 41. Overlay of pre-processed XRPD patterns in multivariate mixture analysis.
    Figure 42. Estimated concentrations of Rifaximin (blue) and HPMC-AS MG (red) using Unscrambler MCR analysis.
    Figure 43. Estimated XRPD patterns of rifaximin (blue) and HPMC-AS MG (red) using Unscrambler MCR analysis.
    Figure 44. Overlay of estimated pure rifaximin XRPD standard using MCR and measured 100% rifaximin XRPD standard.
    Figure 45. Overlay of estimated XRPD pattern of pure HPMC-AS MG using MCR and measured XRPD pattern of 100% HPMC-AS MG.
    Figure 46. An exemplary XRPD pattern for Rifaximin/HPMC-AS MG/Pluronic ternary dispersion combined solids.
    Figure 47. A modular DSC thermogram for Rifaximin/HPMC-AS MG/Pluronic ternary dispersion combined solids.
    Figure 48. A TG-IR analysis for rifaximin/HPMC-AS MG/Pluronic ternary dispersion combined solids - TGA thermogram.
    Figure 49. An exemplary TG-IR analysis for combined solids from the ternary dispersion of rifaximin/HPMC-AS MG/Pluronic.
    Figure 50. An exemplary overlay of IR spectra for X-ray amorphous Rifaximin and combined ternary dispersion solids of Rifaximin/HPMC-AS MG/Pluronic.
    Figure 51. An exemplary overlay of Ramam spectra for X-ray amorphous Rifaximin and combined ternary dispersion solids of Rifaximin/HPMC-AS MG/Pluronic.
    Figure 52. A particle size analysis report for rifaximin/HPMC-AS MG/Pluronic ternary dispersion combined solids.
    Figure 53. An exemplary dynamic vapor sorption (DVS) analysis for the combined solids of the ternary dispersion of Rifaximin/HPMC-AS MG/Pluronic.
    Figure 54. An exemplary overlay of XRPD patterns for Rifaximin/HPMC-AS MG/Pluronic ternary dispersion of post-DVS solids and as-prepared solids.
    Figure 55. An exemplary overlay of XRPD standards for rifaximin dispersion from post-strained samples and sample as prepared.
    Figure 56. An exemplary mDSC thermogram for Rifaximin ternary dispersion after one week at 70°C/75%RH.
    Figure 57. An exemplary mDSC thermogram for ternary dispersion of rifaximin after 3 weeks at 70°C/75% RH.
    Figure 58. An exemplary mDSC thermogram for ternary dispersion of rifaximin after 6 weeks at 40°C/75% RH.
    Figure 59. An exemplary mDSC thermogram for ternary dispersion of rifaximin after 12 weeks at 40°C/75% RH.
    Figure 60. Solid dispersion pharmacokinetic data in dogs.
    Figure 61. Rifaximin SD capsule dissolution; acid phase: 0.1 N HCI, with variable exposure time. Buffer phase: pH 6.8 with 0.45% SDS.
    Figure 62. Rifaximin SD capsule dissolution; acid phase: 2 hours; buffer phase: pH 6.8.
    Figure 63. Dissolution of Rifaximin Capsules; phosphate buffer pH 6.8 with 0.45% SDS.
    Figure 64. Capsule dissolution of the spray-dried dispersion of rifaximin (SDD). (a) acid phase 2 hours, buffer phase: P. buffer, pH 7.4. (b) acid phase: 0.1 N HCI, with various exposure times, buffer phase: P. buffer, pH 7.4 with 0.45% SDS.
    Figure 65. Rifamyxin SDD with 10% CS formulation. (a) Rifamyxin SD granules of kinetic solubility. 10% by weight of CS sodium FaSSIF, 10% by weight of CS sodium FeSSIF. (b) SDD 10% CS tablet dissolution profiles. 0.2% SLS, pH 4.5; 0.2% SLS, pH 5.5; 0.2% SLS, pH 7.4; FaSSIF.
    Figure 66. Rifaximin SDD with 10% CS formulation. dissolution of rifaxamine SDD capsules: (a) acid phase two hours, buffer phase: P. buffer, pH. 7.4. With 0.45% SDS, no SDS. (b) the acid phase: 0.1 N HCI, with variable exposure times, buffer phase: P. buffer, pH 7.4 with 0.45% SDS.
    Figure 67. Effects of medium pH on dissolution, (a) dissolution of rifaxamine SDD tablet. Acid phase: two hours, pH 2.0, (b) 0.2% SDS dissolution profiles at pH 4.5, SDD tablet dissolution at various CS levels: 0%, 2.5%, 5%, and 10% CS.
    Figure 68. Effects of medium pH on dissolution, (a) dissolution of rifaxamine SDD tablet at various CS levels: 0%, 2.5%, 5%, and 10% CS, 0.2% SDS at pH 5.5 (b) Dissolution profiles. SDD tablet dissolution at various CS levels: 0%, 2.5%, 5%, and 10% CS, 0.2% SDS at pH 7.4.
    Figure 69. Effects of medium pH on dissolution, (a) Dissolution of Rifaxamine SDD tablet 2.5% CS, 0.2% SLS, pH 4.5, 0.2% SLS, pH 5.5, 0 .2% SLS, pH 7.4. (b) Rifaxamine SDD tablet solution 0% CS, 0.2% SLS, pH 4.5, 0.2% SLS, pH 5.5, 0.2% SLS, pH 7.4.
    Figure 70. Effects of medium pH on dissolution, (a) dissolution of rifaxamine SDD tablet 10% CS, 0.2% SLS, pH 4.5, 0.2% SLS, pH 5.5, 0.2 % SLS, pH 7.4. (b) Rifaxamine tablet SDD 5% CS, 0.2% SLS, pH 4.5, 0.2% SLS, pH 5.5, 0.2% SLS, pH 7.4.
    Figure 71. CS release mechanism. (a) kinetic solubility in FaSSIF medium, pH 6.5, (b) slope vs. time.
    Figure 72 depicts an overlay of the XRPD patterns of methanol spray-dried quaternary samples of rifaximin. The first is a quaternary rifaximin sample containing 0.063% by weight of BHA. The second is the quaternary sample of rifaximin containing 0.063% by weight of BHT. The third is the quaternary sample of rifaximin containing 0.094% by weight of PG, and the last is a spray-dried ternary dispersion of rifaximin.
    Figure 73 represents an mDSC thermogram of a quaternary sample of rifaximin containing 0.063% by weight of BHA.
    Figure 74 represents an mDSC thermogram of a quaternary sample of rifaximin containing 0.063% by weight of BHT.
    Figure 75 represents an mDSC thermogram of a quaternary sample of rifaximin containing 0.094% by weight of PG.
    Figure 76 represents an XRPD pattern comparison of the 42.48% w/w solid dispersion of rifaximin powder with the roller compacted material of rifaximin mixing. Top: solid dispersion of rifaximin powder 42.48% w/w; Bottom: roller-compacted rifaximin mixture.
    Figure 77 depicts the pharmacokinetics of rifaximin following administration of varying forms and formulations following a single oral dose of 2200 mg in dogs.
    Figure 78 depicts rifaximin SDD in dogs.
    Figure 79 represents the quotient study design.
    Figure 80 summarizes the regional dose increase/uptake study, part A Dose increase/dose selection.
    Figure 81 represents representative susceptible data from a dose escalation study.
    Figure 82 represents representative susceptible data from a dose escalation study.
    Figure 83 represents the mean dose escalation data on a linear scale.
    Figure 84 represents the mean dose escalation data on a log scale.
    Figure 85 represents a summary of the dose escalation studies of rifaximin SDD.
    Figure 86 is a Dose/Dose Form Comparison Table.
    Figure 87 is a Dose/Dose Form Comparison Table. This table compares SDD at increasing doses to the current crystalline formulation in terms of systemic PK. Detailed Description
    The embodiments described herein relate to the discovery of new solid dispersion forms of rifaximin with a variety of polymers and polymeric concentrations. In one embodiment the use of one or more of the new solid dispersion forms of the antibiotic known as rifaximin (INN) in the manufacture of medicinal preparations for the oral or topical route is contemplated. For example, solid dispersion forms of rifaximin are used to create pharmaceutical compositions, for example, tablets or capsules, or microgranules comprising the solid dispersion forms of rifaximin. Exemplary methods for producing rifaximin microgranules are shown in the examples. Rifaximin microgranules can be formulated into pharmaceutical compositions as described herein.
    The modalities described herein also refer to the administration of such medicinal preparations to a subject in need of antibiotic treatment. Provided herein are solid dispersion forms of rifaximin with a variety of polymers and polymer concentrations.
    As used herein, the term "intragranular release controlling agent" includes agents that cause a pharmaceutical composition, for example, a microgranule, to thereby interrupt the release of the active ingredient, for example, rifaximin. Exemplary intragranular release control agent includes disintegrants such as crosprovidone, sodium starch glycolate, corn starch, microcrystalline cellulose, cellulose derivatives, sodium bicarbonate and sodium alginate.
    In one embodiment, the intragranular release control agent comprises from about 2% by weight to about 40% by weight of the microgranule, from about 5% by weight to about 20% by weight of the microgranule, about 8 to 15% by weight or about 10% by weight of the microgranule.
    In another embodiment, the microgranule comprises a surfactant, for example, a non-ionic surfactant. In one embodiment, the nonionic surfactant comprises from about 2% by weight to about 10% by weight of the microgranule, from about 4% by weight to about 8% by weight of the microgranule, from about 6 to about about 7% by weight of the microgranule, or about 5.0% by weight of the microgranule.
    In another embodiment, the microgranule comprises an antioxidant. In one embodiment, the antioxidant comprises between about 0.1% by weight to about 3% by weight of the microgranule, between 0.3% by weight to about 2% by weight, or between about 0.5% by weight to about 1% by weight of the microgranule.
    As used herein, the term "intragranular" refers to those components that reside within the microgranule. As used herein, the term "extragranular" refers to those components of the pharmaceutical composition that are not contained within the microgranule.
    As used herein, the term polymorph is occasionally used as a general term in reference to the forms of rifaximin and includes within context, salt, hydrate, polymorph cocrystal and the amorphous forms of rifaximin. This usage is context dependent and will be evident to a person of technical skill.
    As used herein, the term "about" when used in reference to the maximum positions of the x-ray powder diffraction pattern refers to the inherent variability of the peaks depending, for example, on the calibration of the equipment used, the process. used to produce the polymorph, the age of the crystallized material, and so on, depending on the instrumentation used. In this case, the instrument's measured variability was about ±0.2 degrees 2-0. A person skilled in the art, having the benefit of this disclosure, should understand the use of "about" in this context. The term "about" in reference to other defined parameters, eg water content, Cmax, tmax, AUC, intrinsic dissolution rates, temperature and time, indicates inherent variability, eg in parameter measurement or in obtaining of the parameter. A person skilled in the art, having the benefit of this disclosure, should understand the variability of a parameter as implied by the use of the word about.
    As used herein, "similar" in reference to a form that exhibits similar characteristics to, for example, an XRPD, an IR, a Raman spectrum, a DSC, TGA, NMR, SSNMR, etc., indicates the polymorph or cocrystal is identifiable by the method and may vary from similar to substantially similar, provided that the material is identified by the method with the variations expected by a person of skill in the art according to the experimental variations, including, for example, the instruments used, time of day, humidity, favorable time, pressure, ambient temperature, etc.
    As used herein, "solid dispersion of rifaximin", "ternary dispersion of rifaximin", "solid dispersion of rifaximin", "solid dispersion", "solid dispersion forms of rifaximin", "SD", "SDD", and "solid form dispersion of rifaximin" are intended to have the equivalent meanings and include the polymer dispersion composition of rifaximin. These compositions are amorphous XRPD, but distinguishable from the amorphous rifaximin XRPD. As shown in the Examples and Figures, rifaximin polymer dispersion compositions are physically and chemically distinguishable from amorphous rifaximin, including different Tg, different XRPD profiles and different dissolution profiles.
    Polymorphism, as used herein, refers to the occurrence of different crystalline forms of a single compound in a distinct hydrated state, e.g., a property of some compounds and complexes. Thus, polymorphs are distinct solids that share the same molecular formula, but each polymorph can have distinct physical properties. Therefore, an individual compound can give rise to a variety of polymorphic shapes where each shape has different and distinct physical properties, such as solubility profiles, melting point temperatures, hygroscopic capacity, particle shape, density, fluidity, compactability and/or X-ray diffraction peaks. The solubility of each polymorph can vary, so identifying the existence of pharmaceutical polymorphs is essential to providing pharmaceuticals with predictable solubility profiles. It is desirable to investigate all solid state forms of a drug, including all polymorphic forms, and determine the stability, dissolution and flow properties of each polymorphic form. Polymorphic forms of a compound can be distinguished in a laboratory by X-ray diffraction spectroscopy and by other methods such as infrared spectrometry. For an overview of polymorphs and the pharmaceutical applications of polymorphs see G.M. Wall, Pharm Manuf. 3, 33 (1986); J.K. Haleblian and W. McCrone, J Pharm. Sci., 58, 911 (1969); and J.K. Haleblian, J. Pharm. Sci., 64, 1269 (1975), all of which are incorporated herein by reference.
    As used herein, "individual" includes organisms which are capable of suffering from an intestinal disorder or other disorder treatable by rifaximin or which may otherwise benefit from the administration of solid dispersion compositions of rifaximin as described herein, such as those human and non-human animals. The term "non-human animals" includes all vertebrates, for example, mammals, for example, rodents, for example, mice, and non-mammals, such as non-human primates, for example, sheep, dogs, cows, chickens, amphibians, reptiles, etc. Susceptible to an intestinal disorder means to include individuals at risk of developing an intestinal disorder infection, for example, individuals who suffer from one or more of an immune suppression, individuals who have been exposed to other individuals with a bacterial infection, physicians, nurses, individuals who travel to remote areas known to harbor bacteria that cause travellers' diarrhea, individuals who drink amounts of alcohol that damage the liver, individuals with a history of liver dysfunction, etc.
    The language "a prophylactically effective amount" of a composition refers to an amount of a solid dispersion formulation of rifaximin or otherwise described herein that is effective, upon administration of a single dose or multiple doses to the subject, in preventing or treating a bacterial infection.
    The language "therapeutically effective amount" of a composition refers to an amount of a solid dispersion of rifaximin effective after administering a single dose or multiple doses to the subject to provide a therapeutic benefit to the subject. In one embodiment, the therapeutic benefit is in harming or killing a bacterium, or in prolonging the survivability of an individual with such an intestinal or skin disorder. In another embodiment, the therapeutic benefit is inhibiting a bacterial infection or prolonging the survival of an individual with such a bacterial infection beyond that expected in the absence of such treatment.
    Rifaximin exerts broad antibacterial activity in the gastrointestinal tract against localized gastrointestinal bacteria that cause infectious diarrhea, including anaerobic strains. Rifaximin has been reported to be characterized by negligible systemic absorption due to its chemical and physical characteristics (Descombe JJ et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res, 14 (2), 51 -56, (1994)).
    With regard to possible adverse effects coupled with the therapeutic use of rifaximin, the induction of bacterial resistance to antibiotics is of particular relevance.
    From this point of view, all the differences found in the systemic absorption of the forms of rifaximin disclosed herein may be significant, because the sub-inhibitory concentration of rifaximin, such as in the range of 0.1 to 1 μg/ml, the selection of Resistant mutants have been shown to be possible (Marchese A. et al. In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy, 46 (4), 253-266, (2000)).
    Rifaximin forms, formulations and compositions have been observed to have different bioavailability properties in vivo. Thus, the polymorphs described herein would be useful in the preparation of pharmaceuticals with different characteristics for the treatment of infections. This would allow the generation of rifaximin preparations that have significantly different levels of adsorption with Cmax values of about 0.0 ng/ml to 5.0 µg/ml. This leads to the preparation of rifaximin compositions that are negligibly to significantly adsorbed by individuals undergoing treatment. One modality described herein is the modulation of the therapeutic action of rifaximin by selecting the appropriate form, formulation and/or composition, or mixture thereof, for treating an individual. For example, in the case of invasive bacteria, the most bioavailable form, formulation and/or composition can be selected from those disclosed herein, whereas in the case of non-invasive pathogens less forms, formulations and/or adsorbed compositions of rifaximin can be selected, as that they may be safer for the individual undergoing treatment. A form, formulation and/or composition of rifaximin can determine solubility, which can also determine bioavailability.
    For XRPD analysis, the accuracy and precision associated with third measurements on independently prepared samples on different instruments can lead to variability that is greater than ±0.1° 29. For d-spatial listings, the wavelength used to calculate the d-spacings was 1.541874 A, a weighted average of the Cu-Ka1 and Cu-Ka2 wavelengths. The variability associated with the d-spacing estimates was calculated from the USP recommendation, at each d-spacing, and provided in the respective data tables and maximum lists. Treatment Methods
    Provided herein are methods of treating, preventing, or alleviating related intestinal disorders, comprising administering to a subject in need thereof an effective amount of one or more of the solid dispersion compositions of rifaximin. Related bowel disorders include one or more of irritable bowel syndrome, diarrhea, microbe-associated diarrhea, Clostridium difficile-associated diarrhea, traveler's diarrhea, small bowel bacterial overgrowth, Crohn's disease, diverticulum disease, chronic pancreatitis, pan insufficiency - creatic, enteritis, colitis, hepatic encephalopathy, minimal hepatic encephalopathy or pouchitis.
    The duration of treatment for a particular bowel disorder will depend in part on the disorder. For example, traveler's diarrhea may only require treatment durations of 12 to about 72 hours, whereas Crohn's disease may require treatment durations of about 2 days to 3 months. Rifaximin dosages will also vary depending on the disease state. Appropriate dosage ranges are provided herein below. The polymorphs and cocrystals described herein can also be used to treat or prevent a condition in an individual suspected of being exposed to a biological warfare agent.
    Identifying those individuals who are in need of prophylactic treatment for the bowel disorder is well within the ability and knowledge of a person skilled in the art. Some of the methods for identifying individuals who are at risk of developing a bowel disorder that can be treated by the method in question are seen in the medical arts, such as family history, travel history and expected travel plans, the presence of factors of risks associated with the development of that diseased state in the individual. A physician skilled in the art can easily identify such candidate individuals, through the use of, for example, clinical tests, physical examination, and medical/family/travel history.
    Topical skin infections and vaginal infections can also be treated with the rifaximin compositions described herein. Thus, described herein are methods of using a solid dispersion composition of rifaximin (SD rifaximin compositions) to treat vaginal infections, ear infections, lung infections, periodontal conditions, rosacea, and other infections of the skin and/ or other related conditions. Provided herein are vaginal pharmaceutical compositions for the treatment of vaginal infection, particularly bacterial vaginosis, to be administered topically, including vaginal foams and creams, containing a therapeutically effective amount of SD rifaximin compositions, preferably from about 50 mg and 2500 mg. Pharmaceutical compositions known to those skilled in the art for the topical treatment of vaginal pathological conditions can be advantageously used with the SD rifaximin compositions. For example, vaginal foams, ointments, creams, gels, eggs, capsules, tablets and effervescent tablets can be effectively used as pharmaceutical compositions containing SD rifaximin compositions, which can be administered topically for the treatment of vaginal infections, including bacterial vaginosis. Also provided herein are methods of using SD rifaximin compositions to treat gastric dyspepsia, including gastritis, gastroduodenitis, antral gastritis, antral erosions, erosive duodenitis and peptic ulcers. These conditions can be caused by Helicobacter pylori. Pharmaceutical formulations known to those of skill in the art with the benefit of this disclosure to be used for the oral administration of a drug can be used. Provided here are the methods of treating ear infections with the SD Rifaximin compositions. Ear infections include an outer ear infection, or an infection of the middle and inner ear. Also provided herein are methods of using SD rifaximin compositions to treat or prevent aspiration pneumonia and/or sepsis, including preventing aspiration pneumonia and/or sepsis in patients undergoing acid suppression or who have undergone feedings. artificial enterals through a gastrostomy/jejunostomy or naso/gastric oro tube; the prevention of aspiration pneumonia in patients with impaired mental status, for example, for any reason, for individuals undergoing anesthesia or mechanical ventilation who are at high risk for aspiration pneumonia. Provided herein are methods for treating or preventing periodontal conditions, including plaque, caries and gingivitis. Provided here are methods of treating rosacea, which is a chronic skin condition that involves inflammation of the cheeks, nose, chin, forehead, or eyelids. Pharmaceutical Preparations
    The embodiments also provide pharmaceutical compositions comprising an effective amount of one or more rifaximin SD compositions, or microgranules comprising SD forms of rifaximin described herein (e.g., described herein and a pharmaceutically acceptable carrier). In another embodiment, the effective amount is effective to treat a bacterial infection, for example, small bowel bacterial overgrowth, Crohn's disease, hepatic encephalopathy, antibiotic associated colitis, and/or diverticulum disease. The modalities also provide pharmaceutical compositions comprising an effective amount of rifaximin SD compositions.
    For examples of the use of rifaximin to treat travelers' diarrhea, see Infante RM, Ericsson CD, Zhi-Dong J, Ke S, Steffen R, Riopel L, Sack DA, DuPont, HL, Enteroaggregative Escherichia coliDiarrhea in Travelers: Response to Rifaximin Therapy. Clinical Gastroenterology and Hepatology. 2004;2:135-138; and Steffen R, MD, Sack DA, MD, Riopel L, Ph.D., Zhi-Dong J, Ph.D., Sturchler M, MD, Ericsson CD, MD, Lowe B, M.Phil., Waiyaki P, Ph D., White M, Ph D., DuPont HL, MD Therapy of Travelers' Diarrhea With Rifaximin on Various Continents. The American Journal of Gastroenterology. May 2003, Volume 98, Number 5, all of which are incorporated herein by reference in their entirety. Examples of treatment of hepatic encephalopathy with rifaximin see, for example, N. Engl J Med. 2010-362-1071-1081.
    The modalities also provide pharmaceutical compositions comprising SD rifaximin compositions and a pharmaceutically acceptable carrier. The modalities of the pharmaceutical composition further comprise excipients, eg one or more of a diluting agent, binding agent, lubricating agent, intragranular release control agent, eg a disintegrating agent, coloring agent, flavoring or sweetening agent . A composition can be formulated for selected coated and uncoated tablets, solid and soft gelatin capsules, sugar coated pills, lozenges, lozenges, granules, and powders in sealed packages. For example, the compositions can be formulated for topical use, for example, ointments, ointments, creams, gels and lotions.
    In one embodiment, the SD rifaximin composition is administered to the subject using a pharmaceutically acceptable formulation, for example, a pharmaceutically acceptable formulation that provides sustained or delayed release of the SD rifaximin composition in an individual for at least 2, 4, 6, 8, 10, 12 hours, 24 hours, 36 hours, 48 hours, one week, two weeks, three weeks or four weeks after the pharmaceutically acceptable formulation has been administered to the subject. Pharmaceutically acceptable formulations may contain microgranules comprising rifaximin as described herein.
    In certain embodiments, these pharmaceutical compositions are suitable for topical or oral administration to a subject. In other embodiments, as described in detail below, the pharmaceutical compositions described herein may be specially formulated for administration in solid or liquid form, including those adapted for the following: (1) oral administration, e.g., liquid remedies (solutions or suspensions aqueous or non-aqueous), tablets, large pills, powders, granules, pastes; (2) parenteral administration, for example, by subcutaneous, intramuscular or intravenous injection as, for example, a sterile solution or suspension; (3) topical application, for example, as a cream, ointment or spray applied to the skin; (4) intravaginally or intrarectally, for example, as a vaginal suppository, cream or foam; or (5) aerosol, for example, as an aqueous aerosol, liposome preparation, or solid particles containing the compound.
    The phrase "pharmaceutically acceptable" refers to those rifaximin SD and co-crystal compositions provided herein, compositions containing such compounds, and/or dosage forms that are, within the scope of safe medical judgment, suitable for use in contact with the tissues from humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, consistent with a reasonable benefit/risk ratio.
    The phrase "pharmaceutically acceptable carrier" includes the pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, solvent or encapsulating material, involved in loading or transporting the chemical in question from an organ. , or part of the body, to another organ, or part of the body. Each carrier is preferably "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the individual. Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars such as lactose, glucose and sucrose, (2) starches such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerin, glycol, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline solution; (18) Ringer's solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances used in pharmaceutical formulations.
    Wetting agents, emulsifiers and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweeteners, flavoring and perfuming agents, preservatives and antioxidants may also be present in the compositions .
    Examples of pharmaceutically acceptable antioxidants include: (1) water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite and more, (2) oil-soluble antioxidants such as palmitate of ascorbyl, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, alpha-tocopherol, and others; and (3) metal chelating agents, such as citric acid, ethylenediamine tetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, and so on.
    Methods of preparing these compositions include the step of bringing into association a rifaximin SD composition or microgranules containing the rifaximin SD compositions with the carrier and, optionally, one or more accessory ingredients. In general, formulations are prepared by uniformly and intimately bringing into association a rifaximin SD composition with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, molding the product.
    Compositions suitable for oral administration may be in the form of capsules, seals, pills, tablets, lozenges (using a flavored base, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous liquid. or non-aqueous, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as lozenges (using an inert base such as gelatin and glycerin, or sucrose and acacia ) and/or as mouthwashes and the like, each containing a predetermined amount of an SD rifaximin composition as an active ingredient. A compost can also be administered as a cake, electuary or paste.
    The SD compositions of rifaximin disclosed herein can be advantageously used in the production of medicinal preparations having antibiotic activity, containing rifaximin, for both oral and topical use. Medicinal preparations for oral use will contain an SD composition of rifaximin together with customary excipients, for example, diluting agents such as mannitol, lactose and sorbitol; binding agents such as starches, gelatins, sugars, cellulose derivatives, natural gums and polyvinylpyrrolidone; lubricating agents such as talc, stearates, hydrogenated vegetable oils, polyethylene glycol and colloidal silicon dioxide; disintegrating agents such as crosslinked starches, celluloses, alginates, gums and polymers; coloring, flavoring, disintegrating, and sweetening agents.
    The embodiments described herein include orally administrable SD rifaximin compositions, for example, coated and uncoated tablets, soft and solid gelatin capsules, sugar coated pills, lozenges, lozenge sheets, granules, and powders in sealed packages or other containers.
    Pharmaceutical compositions for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing one or more SD soft rifaximin compositions with one or more suitable non-irritating excipients or carriers comprising, for example, cocoa butter , polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature but liquid at body temperature and therefore will melt in the rectum or vaginal cavity and release the active agent. Compositions which are suitable for vaginal administration also include vaginal suppositories, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
    Dosage forms for the topical or transdermal administration of a rifaximin SD composition include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches and inhalants. The active SD rifaximin composition can be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propellants that may be needed.
    Ointments, pastes, creams and gels may contain, in addition to SD rifaximin compositions, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, acid silicic, talc and zinc oxide, or mixtures thereof.
    Powders and sprays may contain, in addition to an SD rifaximin composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons and volatile unsubstituted hydrocarbons such as butane and propane.
    Rifaximin SD compositions may alternatively be administered by aerosol. This is accomplished by preparing an aqueous aerosol, preparing liposomes or solid particles containing the compound. Non-aqueous suspension (eg, fluorocarbon propellant) can be used. Sonic nebulizers are preferred because they minimize the agent's exposure to shear, which can result in compound degradation.
    An aqueous aerosol is produced, for example, by formulating an aqueous solution or suspension of the agent together with conventional pharmaceutically acceptable carriers and stabilizers. Carriers and stabilizers vary with the requirements of the particular compound, but typically include nonionic surfactants (Tweens, Pluronics or polyethylene glycol), innocuous proteins such as serum albumin, sorbitan esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars or sugar alcohols. Aerosols are generally prepared from isotonic solutions.
    Transdermal patches have the added advantage of providing controlled release of an SD rifaximin composition into the body. Such dosage forms can be prepared by dissolving or dispersing the agent in the proper medium. Absorption enhancers can also be used to increase the flux of the active ingredient through the skin. The rate of such flux can be controlled by providing a rate controlling membrane or by dispersing the active ingredient in a polymer matrix or gel.
    Ophthalmic formulations, eye ointments, powders, solutions and the like are also contemplated as being within the scope of the invention. Pharmaceutical compositions suitable for parenteral administration may comprise one or more rifaximin SD compositions in combination with one or more pharmaceutically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders which can be reconstituted into solutions or dispersions sterile injectables immediately before use, which may contain antioxidants, buffers, bacteriostatic agents, solutes that make the formulation isotonic with the intended recipient's blood, or suspending or thickening agents.
    Examples of suitable aqueous and non-aqueous carriers that can be employed in pharmaceutical compositions include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils such as oil. of olive, and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, through the use of coating materials such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants.
    When the SD rifaximin composition is administered as pharmaceuticals, for humans and animals, it can be provided per se or as a pharmaceutical composition containing, for example, from 0.1 to 99.5% (more preferably, 0.5 to 90%) of active ingredient in combination with a pharmaceutically acceptable carrier.
    Regardless of the route of administration selected, rifaximin SD compositions are formulated into pharmaceutically acceptable dosage forms by methods known to those skilled in the art.
    The actual dosage levels and time course of administration of the active ingredients in the pharmaceutical compositions can be varied in order to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response with respect to a particular individual, composition and mode of administration , without being toxic to the individual. An exemplary dose range is 25 to 3000 mg per day. Other doses include, for example, 600 mg/day, 1100 mg/day and 1650 mg/day. Other exemplary doses include, for example, 1000 mg/day, 1500 mg/day, between 500 mg to about 1800 mg/day, or any value in between.
    A preferred dose of the SD rifaximin composition disclosed herein is the maximum an individual can tolerate without developing serious side effects. Preferably, the SD rifaximin composition is administered at a concentration of about 1 mg to about 200 mg per kilogram of body weight, about 10 to about 100 mg/kg, or about 40 mg to about 80 mg /kg of body weight. The middle ranges for the values recited above are also meant to be part. For example, doses can range from 50 mg to about 2000 mg/day.
    In combination therapy treatment, the other drug agents are administered to mammals (e.g., humans, males or females) by conventional methods. The agents can be administered in a single dosage form or in separate dosage forms. Effective amounts of the other therapeutic agents are well known to those skilled in the art. However, it is well within the purview of the skilled artisan to determine the optimal effective amount range of the other therapeutic agent. In an embodiment where another therapeutic agent is administered to an animal, the effective amount of the SD rifaximin composition is less than its effective amount in the case where the other therapeutic agent is not administered. In another embodiment, the effective amount of the conventional agent is less than its effective amount in the case where the SD rifaximin composition is not administered. In this way, unwanted side effects associated with the high doses of each agent can be minimized. Other potential advantages (including without limitation improved dosing regimens and/or reduced drug cost) will be apparent to those skilled in the art.
    In various modalities, therapies (eg, prophylactic or therapeutic agents) are administered less than 5 minutes apart, less than 30 minutes apart, 1 hour apart, around 1 hour apart, about 1 about 2 hours apart, about 2 hours to about 3 hours apart, about 3 hours to about 4 hours apart, about 4 hours to about 5 hours apart, from about 5 hours to about 6 hours apart, about 6 hours to about 7 hours apart, about 7 hours to about 8 hours apart, about 8 hours to about 9 hours apart , from about 9 hours to about 10 hours apart, from about 10 hours to about 11 hours apart, from about 11 hours to about 12 hours apart, around 12 hours to 18 hours apart , from 18 hours to 24 hours apart, from 24 hours to 36 hours apart, from 36 hours to 48 hours apart, from 48 hours to 52 hours of range, 52 hours to 60 hours apart, 60 hours to 72 hours apart, 72 hours to 84 hours apart, 84 hours to 96 hours apart, or 96 hours to 120 hours apart. In preferred modalities, two or more therapies are administered within the same individual visit.
    In certain embodiments, one or more compounds and one or more other therapies (for example, prophylactic or therapeutic agents) are administered cyclically. Cyclic therapy involves administering a first therapy (eg, a first prophylactic or therapeutic agent) over a period of time, followed by administering a second therapy (eg, a second prophylactic or therapeutic agent) over a period of time. , optionally followed by administering a third therapy (eg, prophylactic or therapeutic agent) over a period of time and so on, and repeating this administration sequentially, ie, the cycle in order to reduce the development of resistance to one. of the therapies, to prevent or reduce the side effects of one of the therapies, and/or to improve the effectiveness of the therapies.
    In certain embodiments, administration of the same compounds may be repeated and administrations may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days , 3 months, or at least 6 months. In other modalities, administration of the same therapy (e.g., prophylactic or therapeutic agent) other than an SD rifaximin composition may be repeated and administration may be separated by at least 1 day, 2 days, 3 days, 5 days, 10 days, 15 days, 30 days, 45 days, 2 months, 75 days, 3 months, or at least 6 months.
    Certain indications may require longer treatment times. For example, a traveler's diarrhea treatment may only last between about 12 hours to about 72 hours, whereas a treatment for Crohn's disease can be between about 1 day to about 3 months. A treatment for hepatic encephalopathy can be, for example, for the rest of a person's lifetime. A treatment for IBS can be intermittent for weeks or months at a time or for the rest of an individual's life. Compositions and Formulations
    Solid dispersions of rifaximin, pharmaceutical compositions comprising SD of rifaximin or microgranules comprising solid dispersions of rifaxmin, can be prepared from, for example, polymers including K-90 grade polyvinylpyrrolidone (PVP), methylcellulose hydroxypropyl phthalate (HPMC-P ) grade 55, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) grades HG and MG, and a polymethacrylate (Eudragit® L100-55). Rifaximin solid dispersion compositions are comprised of, for example, 10:90, 15:85, 20:80, 25:75, 30:70, 40:60, 50:50, 60:40, 70:30, 75:25, 80:20, 85:15 and 90:10 (rifaximin/polymer, by weight). Preferred solid dispersions are comprised of 25:75, 50:50 and 75:25 (rifaximin/polymer, by weight). In addition to rifaximin and polymer, solid dispersions may also comprise surfactants, for example nonionic surfactant polyols.
    An example of a formulation comprises about 50:50 (w/w) rifaximin:HPMC-AS MG with between about 2% by weight to about 10% by weight of a nonionic surfactant polyol, e.g., Pluronic F -127.
    An example of a formulation comprises 50:50 (w/w) rifaximin:HPMC-AS MG with about 5.9% by weight of a nonionic surfactant polyol, eg Pluronic F-127. The spray-dried ternary dispersion of rifaximin (50:50 (w/w) rifaximin:HPMC-AS MG with 5.9% by weight Pluronic F-127) was mixed with 10% by weight of croscarmellose sodium and then loaded into gelatin capsules. Each capsule contains 275 mg of rifaximin and the blend formulation is 85:5:10 to 50:50 (w/w) rifaximin:HPMC-AS MG : Pluronic : croscarmellose sodium (calculated on total solids). Other examples of microgranules and pharmaceutical compositions comprising rifaximin SD are described in the examples.
    To form the solid dispersion of rifaximin, the components, for example, rifaximin, polymer and methanol are mixed and then spray dried. Exemplary conditions are summarized in Table 9 and the procedure outlined below and in Examples 3 and 4.
    Exemplary spray drying process parameters include, for example: • Spray Dryer - eg PSD 1; • Single or multiple fluid nozzle: for example, a double Fluid Niro nozzle; • Nozzle orifice - 0.1 to 10 mm; • Inlet gas temperature - 75 to 150 ± 5 °C; • process gas flow (mmH20) - 20 to 70, preferable 44; • Atomizing gas pressure - 0.7 to 1 bar; • Feed rate - 2 to 7 kg/h; • Outlet temperature - 30 to 70 ± 3°C; • Solution temperature - 20 to 50°C, and • Vacuum drying after spray drying at 20 to 60°C for between about 2 and 72 hours. Article of Manufacture
    Another embodiment includes articles of manufacture comprising, for example, a container holding an SD pharmaceutical composition of rifaximin suitable for oral or topical administration of rifaximin in combination with printed labeling instructions that provide a rationale for when a dosage form is particular should be given with food and when it should be taken on an empty stomach. Exemplary dosage forms and administration protocols are described below. The composition will be contained in any suitable container capable of holding and dispensing the dosage form and which does not significantly interact with the composition and will still be in physical relationship to the appropriate labeling. The labeling instructions will be consistent with the treatment methods as described further above. The labeling may be associated with the container by any means that maintain physical proximity of the two, by way of non-limiting example, they may be contained in a packaging material such as a plastic shrink box or wrap or they may be as- associated with instructions that are attached to the container, such as with glue that does not obscure the labeling instructions or other means of attachment or retention.
    Another aspect is an article of manufacture comprising a container containing a pharmaceutical composition comprising the SD composition or formulation of rifaximin wherein the container preferably holds the rifaximin composition in unit dosage form, and is associated with printed labeling instructions which recommends different absorption when the pharmaceutical composition is taken with and without food.
    Packaged compositions are also provided, and may comprise a therapeutically effective amount of rifaximin.
    The SD composition of rifaximin is a pharmaceutically acceptable carrier or diluent, wherein the composition is formulated to treat an individual suffering from or susceptible to an intestinal disorder, and packaged with instructions for treating an individual suffering from or susceptible to an intestinal disorder.
    Kits are also provided herein, for example kits for treating an intestinal disorder in an individual. Kits may contain, for example, one or more of the solid dispersion forms of rifaximin and instructions for use. Instructions for use may contain prohibited information, dosage information, storage information, and 20 more.
    Packaged compositions are also provided, and may comprise a therapeutically effective amount of an SD rifaximin composition and a pharmaceutically acceptable carrier or diluent, wherein the composition is formulated for treating an individual suffering from or susceptible to an intestinal disorder. , and packaged with instructions for treating an individual suffering from or susceptible to an intestinal disorder.
    The present invention is further illustrated by the following examples, which are not to be construed as another limitation. The contents of all figures and all references, patents and published patent applications cited throughout this application, as well as the Figures, are hereby expressly incorporated by reference in their entirety. Examples
    The chemical structure of rifaximin is shown below in Figure 1. Example 1. Solid Dispersions of Rifaximin
    Various polymers have been formulated with rifaximin in solids prepared by methanol and spray drying on a small scale (~1 g). The polymers including polyvinylpyrrolidone (PVP) grade K-90, methylcellulose hydroxypropyl phthalate (HPMC-P) grade 55, hydroxypropyl methylcellulose acetate succinate (HPMC-AS) grades HG and MG, and a polymethacrylate (Eudragit® L100-55) , were used. The solids have compositions of 25:75, 50:50 and 75:25 (rifaximin/polymer, by weight).
    The generated samples were observed under a polarized optical microscope after preparation and were characterized by XRPD. The results are included in Table 1 through Table 5. Extinction birefringence (B/E) was not observed for any of the samples, indicating that solids without crystalline order were obtained. No sharp maximum was evident by visual inspection of the XRPD patterns of these samples, according to the non-crystalline materials, as shown in Figure 2 (with PVP K-90), Figure 7 (with HPMC-P), Figure 12 (with HMPC-AS HG), Figure 12 (with HMPC-AS MG), and in Figure 17 (with Eudragit L100-55).
    The materials were characterized by mDSC where the appearance of a single glass transition temperature (Tg) provides support for a fully miscible non-crystalline dispersion. All dispersions prepared with PVP K-90 exhibit a single apparent Tg of approximately 185°C (Figure 3, 25:75 w/w), 193°C (Figure 4, 50:50 w/w), and 197°C (Figure 5, 75:25), respectively. The change in thermal capacity (ΔCp) in Tg is approximately 0.3 J/g*°C for each dispersion. Non-reversible endotherm, which is likely due to residual solvent in the materials, was observed in each of the rifaximin/PVP K-90 dispersions centered at approximately 78°C, 59°C and 61°C.
    From Figure 6, the Tg of rifaximin/PVP K-90 dispersions increases with increased concentration of rifaximin, which is due to the higher Tg of rifaximin (199°C) than PVP K-90 (174°C) . Evidence for a single Tg may suggest that the components of the dispersion are intimately mixed, or miscible.
    Dispersions prepared with other polymers also show a single apparent Tg, as a step change in the reversal of the heat flux signal by mDSC. Dispersions prepared with HPMC-P show Tg at 153°C (Figure 8, 25:75 w/w), 161°C (Figure 9, 50:50 w/w) and 174°C (Figure 10, 75:25 w/w) respectively, with ΔCp at a Tg of approximately 0.4 J/g*°C.
    With HPMC-AS HG, the dispersions have a Tg of 137°C (Figure 13, 25:75 w/w), 154°C (Figure 14, 50:50 w/w) and 177°C (Figure 15, 75: 25 w/w), respectively; ΔCp at Tg is approximately 0.4 or 0.3 J/g-°c.
    With HPMC-AS MG, the dispersions had a Tg of 140°C (Figure 18, 25:75 w/w), 159°C (Figure 19, 50:50 w/w) and 177°C (Figure 10, 75: 25 w/w), respectively; ΔCp at Tg is approximately 0.4 or 0.3 J/g-°c.
    Dispersions prepared with Eudragit L100-55 have a Tg of 141°C with a ΔCp of approximately 0.5 J/g*°C (Figure 23, 25:75 w/w), 159°C, with a ΔCp of approximately 0.3 J/g*°C (Figure 24, 50:50 w/w), and 176°C with ΔCp at Tg of approximately 0.2 J/g*°C (Figure 25, 75:25 w/w), respectively.
    Similarly, as shown in Figure 11 (with HPMC-P), Figure 16 (with HPMC-AS HG), Figure 21 (with HPMC-AS MG), and Figure 26 (with Eudragit L100-55), the Tg of the material in each set of rifaximin/polymer dispersions increases with increased rifaximin concentration due to the higher Tg of rifaximin. Physical Stability Assessment
    An evaluation of the physical stability of rifaximin/polymer dispersions was conducted under stress conditions of aqueous solutions under different biologically relevant conditions, including 0.1 N HCI solution at 37°C and pH 6.5 FASSIF buffer at 37 °C, high temperature/relative humidity (40°C/75% RH), and high temperature/drying (60°C). The x-ray amorphous rifaximin - only the methanol sample prepared by spray drying was also strained under the same conditions for comparison. Voltage in 0.1 N HCI Solution at 37°C
    For the evaluation of physical stability for the samples in a 0.1 N HCI solution kept at 37°C, observations were made and microscopy images were acquired using polarized light at different times, including 0, 6 and 24 hours, as summarized in Table 6. Based on the absence of birefringent particles when the samples were observed by PLM, dispersions prepared with HPMC-AS HG and HPMC-AS MG exhibit the greatest physical stability under this particular stress condition. The results of this study for each of the samples are discussed below.
    X-ray amorphous rifaximin subjected to stress in 0.1 N HCI at 37°C at 0, 6 and 24 hours showed evidence of birefringence/extinctions was observed at 6 hours, which indicates the occurrence of devitrification of the material.
    Samples in the compositions of 25:75 and 50:50 (w/w) crystallized in 6 hours; 75:25 (w/w) samples the composition crystallized within 24 hours, whereas no evidence of crystallization was observed at 6 hours or earlier. The reduced stability of rifaximin/PVP K-90 dispersions in 0.1 N HCI solution with increased PVP K-90 concentration may be due to the high solubility of PVP K-90 in the solution.
    Irregular aggregates without birefringence/extinctions were observed in relation to the dispersion prepared with HPMC-P at t = 0 h, the initial moment when the 0.1 N HCI solution was added to solids only. After 24 hours, the samples in the compositions of 25:75 and 50:50 (w/w) remained as non-birefringent aggregates, which indicates that there was no occurrence of devitrification under the conditions examined. Evidence of crystallization was seen for the 75:25 (w/w) composition sample at 6 hours. No birefringence/extinction was observed for all dispersions prepared with HPMC-AS HG and HPMC-AS MG after 24 hours, suggesting that these samples are resistant to devitrification after exposure to 0.1 N HCI solution for 24 hours.
    For dispersions prepared with Eudragit L100-55, after exposure to the 0.1 N HCI solution for 24 hours, birefringent particles with extinctions were observed only in the sample of composition 50:50 (w/w). Considering that no evidence of crystallization was observed for the dispersions of the compositions at 25:75 and 75:25 (w/w), it is unknown whether such birefringence was caused by some foreign materials or by crystalline solids which indicates the occurrence of devitrification . Voltage with pH 6.5 FASSIF buffer at 37°C
    An evaluation of the physical stability of the prepared dispersions was also performed in pH 6.5 FASSIF buffer maintained at 37°C. The X-ray amorphous Rifaximin material was also stressed under the same condition for comparison. PLM observations indicated that dispersions prepared from HPMC-AS HG and HPMC-AS MG have the greatest physical stability under this stress condition. The X-ray amorphous rifaximin-only material crystallized within 6 hours, as did all rifaximin/PVP K-90 dispersions. For dispersions prepared with HPMC-P, birefringent particles with extinctions were observed in samples in compositions 50:50 and 75:25 (w/w) within 6 hours, which indicates the occurrence of devitrification in the materials. No evidence of any birefringence/extinctions was observed in the 25:75 (w/w) rifaximin/HPMC-P dispersion material after 24 hours. No birefringence/extinction was observed for all dispersions prepared with HPMC-AS HG and HPMC-AS MG after 24 hours, suggesting that these samples are resistant to devitrification after exposure to pH 6.5 FASSIF buffer for 24 hours. Dispersions of Rifaximin/Eudragit L100-55 in compositions 50:50 and 75:25 (w/w) crystallized after 6 hours, while no evidence of crystallization was observed in the sample of composition 25:75 (w/w) after 24 hours. Voltage at 40°C/75% RH condition
    Samples including all dispersions and material only of amorphous x-ray rifaximin were evaluated for evidence of crystallization based on observations by polarized light microscopy. Each of the samples remained as irregular aggregates without birefringence/extinctions after stressing at 40°C/75% RH for 7 days.
    Modulated DSC analyzes were performed on selected samples including 25:75 (w/w) rifaximin/HPMC-P, 75:25 (w/w) rifaximin/HPMC-AS HG, 75:25 (w/w) rifaximin/HPMC-AS MG, and 25:75 (w/w) rifaximin/Eudragit L100-55 to inspect for evidence of phase separation after exposure to 40°C/75%RH for 7 days. All samples show a single apparent Tg of approximately 148°C (Figure 27, 25:75 (w/w) of HPMC-P), 177°C (Figure 28, 75:25 (w/w) HPMC-AS HG ) 152°C (Figure 29, 75:25 (w/w) of HPMC-AS MG) and 140°C (Figure 30, 25:75 (w/w) Eudragit L100-55) respectively, indicating that the components of each scatter remained intimately miscible after strain. Although fixed with a manual pin hole the DSC autoclave was used, the release of moisture from the sample after heating can still be observed from the non-reversible heat flow signals. Voltage at 60°C/drying condition
    All dispersions and x-ray amorphous rifaximin-only material were also stressed at 60°C/drying for 7 days and were evaluated for evidence of crystallization based on observations by microscopy using polarized light. Each of the samples remained as irregular aggregates without birefringence/extinctions after being stressed in this condition for 7 days. Solid Dispersions of Rifaximin by Spray Drying
    Based on the experimental screening results, HPMC-AS MG and HPMC-P were used to prepare additional amounts of solid gram-scale dispersions by spray drying. The operational parameters used for processing are presented in Table 9. Based on visual inspection, both dispersions were amorphous to x-ray by XRPD (Figure 31 and Figure 36). Characterization of 50:50 Dispersion (w/w) Rifaximin/HPMC-AS MG
    The characterization and results for the 50% API bearing HPMC-AS MG are summarized in Table 10. The sample was x-ray amorphous based on high resolution XRPD. The single Tg at approximately 154°C was observed from the apparent step change in the inversion of the heat flux signal in mDSC with the 0.4 J/g °C heat capacity change. Non-reversible endotherm was observed at approximately 39°C which is likely due to residual solvent in the materials (Figure 32). TG-IR analysis was performed in order to determine the volatiles content on heating. The TGA data for this material is shown in Figure 34. There was a 0.5% weight loss down to ~100°C. The Gram-Schmidt plot corresponding to the global IR intensity associated with volatiles released by solids after heating at 20°C/min is shown in Figure 33. There was a dramatic increase in the intensity of volatiles released after ~8 minutes, with a maximum of -11.5 minutes. The cascade plot (Figure 34) and on-IR spectrum (Figure 35) are indicative of water loss up to -8 minutes, then methanol and some unknown volatiles thereafter. This is consistent with the dramatic change in TGA slope and may indicate material decomposition. Characterization of the Dispersion of 25:75 (w/w) rifaximin/HPMC-P
    The characterization and results for the 25% API bearing the HPMC-P dispersion are summarized in Table 11. The solids were amorphous to x-ray based on the high resolution XRPD (Figure 36). By mDSC, there is a single Tg of approximately 152°C from the apparent step change in the reversal of the heat flux signal. The change in thermal capacity is 0.4 J/g °C (Figure 37). Non-reversible endotherm, which is likely due to residual solvent in the materials, was observed at approximately 46°C. Volatiles generated in heating were analyzed by TG-IR. The total weight loss of the sample was approximately 1.5% by weight at 100°C and the dramatic change in slope occurs at approximately 178°C (Figure 38). The Gram-Schmidt plot (Figure 39) shows a small increase in intensity after warming up after ~2 minutes, followed by a negligible change in intensity until ~9 minutes. Then the dramatic change in intensity can be seen with a maximum of -11 minutes, followed by a final increase in intensity above ~12 minutes. As seen in the waterfall graph (Figure 39), some volatiles were released during the entire heating period (data are shown in Figure 40 using the IR spectrum turned on at different times as an example). The sample released water during the entire heating period and methanol after ~9 minutes. Study of the Miscibility of Dispersions through Multivariate Mixture Analysis
    For rifaximin/HPMC-AS MG dispersions prepared by spray drying, a multivariate mixture analysis was performed using the XRPD data to examine the physical state of the components and inspect for evidence of miscibility. The analysis was done with MATLAB (v7.6.0) and Unscrambler (v 9.8) and was not performed under cGMP guidelines. The XRPD patterns of all samples were truncated with their baseline corrected, and unit area normalized prior to analysis. The pre-dominated XRPD patterns are shown in Figure 41.
    In the analysis, rifaximin and HPMC-AS MG were assumed to be separate phases (no miscibility) and the compositions of rifaximin and HPMC-AS MG in each sample were estimated based on this assumption. As shown in Figure 42, the estimated ratios of rifaximin to HPMC-AS MG based on the pure separated phases do not match the actual compositions of the samples, especially for the samples with higher compositions of HPMC-AS MG (low rifaximin loading). Similarly, calculated XRPD standards for rifaximin and HMPC-AS MG based on the assumption of separate phases (Figure 43) compared to actual experimental XRPD standards for rifaximin (Figure 44) and HPMC-AS MG (Figure 45 ) were generated. Although the calculated rifaximin pattern is similar to your experimental pattern, the calculated HMPC-AS MG pattern is very different from your experimental pattern. Both results suggest that rifaximin and HPMC-AS MG are not separate phases, but are miscible in the dispersions. The differences in estimated and actual compositions are likely due to the interaction between rifaximin and HPMC-AS MG. Table 1. Solid Dispersion Attempts for Rifaximin/PVP K-90 by Spray Drying
    (a): approximate ratio of Rifaximin to polymer, by weight; (b): samples stored in the refrigerator with desiccant after preparation. Table 2. Solid Dispersion Attempts for Rifaximin/HPMC-P by Spray Drying
    (a): approximate ratio of Rifaximin to polymer, by weight; (b): samples stored in the refrigerator with desiccant after preparation. Table 3. Solid Dispersion Attempts for Rifaximin/HPMC-AS HG by Spray Drying
    (a): approximate ratio of Rifaximin to polymer, by weight; (b): samples stored in the refrigerator with desiccant after pre- Table 4. Solid Dispersion Attempts for Rifaximin/HPMC-AS MG by Spray Drying
    (a): approximate ratio of Rifaximin to polymer, by weight; (b): samples stored in the refrigerator with desiccant after preparation. Table 5. Solid Dispersion Attempts for Rifaximin/Eudragit L100-55 by Spray Drying
    (a): approximate ratio of Rifaximin to polymer, by weight; (b): samples stored in the refrigerator with desiccant after pre- Table 6.
    Evaluation of Physical Stability in 0.1N HCI at 37°C for Rifaximin Rifaximin Prepared in Methanol by Se- Spray
    ximina and Di caqem per (a): approximate ratio of Rifaximine to polymer, by weight. (b): time is cumulative and approximate; 100 μL of 0.1 N HCI solution added to the samples at t = 0. (c): 100 μL of 0.1 N HCI solution added to the sample after PLM analysis at 6 h. Table 6 (cont'd) Physical Stability Assessment in 0.1 N HCI at 37°C for Rifaximin and Rifaximin Dispersions Prepared in Methanol by Spray Drying

    Table 6 (cont'd) Physical Stability Assessment in 0.1 N HCI at 37°C for Rifaximin and Rifaximin Dispersions Prepared in Methanol by Spray Drying
    Table 6 (cont'd) Physical Stability Assessment in 0.1N HCI at 37°C for Rifaximin and Rifaximin Dispersions Prepared in Methanol by Spray Drying
    Table 7 Evaluation of Physical Stability at 40°C/75% RH/7 d Condition for Rifaximin and Rifaximin Dispersions Prepared in Methanol by Spray Drying
    (a): approximate ratio of Rifaximin to polymer, by weight. (b): analysis treated as without cGMP. Table 8, Physical Stability Assessment at 60°C/Dry/7 d Condition for Rifaximin and Rifaximin Dispersions Prepared in Methanol by Spray Drying
    (a): approximate ratio of Rifaximin to polymer, by weight. Table 9. Retro Pu Drying for Solid Dispersions of Rifaximin by Verification
    (a): approximate ratio of Rifaximin to polymer, by weight. (b): Flow rates are estimated at 30% at the pump. Table 10. 50:50 characterizations (w/w) Dispersion of Rifaximin/HPMC-AS MG through Spray Drying
    Table 11 Characterizations of 25:75 (w/w) Rifaximin/HPMC-P Dispersion by Spray Drying
    Table 12. Rifaximin Dispersions Sample Information for the Dissolve Bread Test at pH 3.52 FASSIF Buffer at 37°C
    (a): approximate ratio of Rifaximin to polymer, by weight. Table 13. Rifaximin Concentrations of 50:50 (w/w) Rifaximin/HPMC-AS MG Dispersion at pH 6.52 FASSIF Buffer at 37°C
    (c): Certain samples were diluted prior to analysis to avoid the possibility of falling outside the instrument's linearity range. (d): Absorbance data less than 0.05 are below the instrumental detection limit and therefore the calculated concentration of such absorbance is an approximate value. Table 14. Rifaximin Concentrations 25:75 (w/w) Rifaximin/HPMC-P Dispersion at pH 6.52 FASS F Buffer at 37°C
    (c): Certain samples were diluted prior to analysis to avoid the possibility of falling outside the instrument's linearity range. (d): Absorbance data less than 0.05 are below the instrumental detection limit and therefore the calculated concentration of such absorbance is an approximate value. Table 15. Concentrations na/HPMC-AS MGs at Mean pH es of 50.50 (w/w) Rifaximi Dispersion- 6.52 FASSIF Buffer at 37°C
    (a): approximate ratio of Rifaximin to polymer, by weight. (b): Absorbance data less than 0.05 are below the instrumental detection limit and therefore the calculated concentration of such absorbance is an approximate value. Table 16. Concentrations/HPMC-Ps at pH 6.52 n i Means 25:75 (w/w) Dispersion of Rifaximi-fampão FASSIF at 37°C
    (a): approximate ratio of Rifaximin to polymer, by weight. (b): Absorbance data less than 0.05 are below the instrumental detection limit and therefore the calculated concentration of such absorbance is an approximate value. Table 17. Analysis of Rifaximin Dispersions after the Dissolution Test at pH 6.52 FASSIF Buffer at 37°C
    (a): approximate ratio of Rifaximin to polymer, by weight. Abbreviations
    Example 2. Ternary dispersion of 50:50 (w/w) rifaximin: HPMC-AS MG
    A ternary dispersion of 50:50 (w/w) rifaximin:HPMC-AS MG with 5.9% by weight of Pluronic F-127 was prepared in bulk (containing approximately 110 g of rifaximin) by spray drying. Disclosed herein are the analytical characterizations for the as-prepared and post-stress samples of the ternary dispersion of rifaximin at 70°C/75% RH for one week and 3 weeks, and post-strain sample at 40°C/75% RH for 6 weeks and 12 weeks. Characterization of Rifaximin Ternary Dispersion
    Characterizations of the spray-dried ternary dispersion of rifaximin (50:50 (w/w) rifaximin:HPMC-AS MG with 5.9 wt% Pluronic F-127) are described in Table 18. Table 18. Solid Characterizations Rifaximin Ternary Dispersion Combined
    (b): temperatures are rounded to the nearest degree; ΔCp is rounded to one decimal place and % by weight is rounded to one decimal place.
    A high resolution XRPD pattern was acquired and the material is amorphous on x-ray (Figure 46). By mDSC (Figure 47), a single apparent Tg is observed from the step change in the heat flux signal inversion at approximately 136°C with a thermal capacity change in Tg of about 0.4 J/g* °C.
    Thermogravimetric analysis coupled with infrared spectroscopy (TG-IR) was performed to analyze the volatiles generated after heating. The total weight loss of the sample was approximately 0.7% by weight at 100°C and the dramatic change in slope occurs at approximately 202°C (Figure 48). The Gram-Schmidt plot corresponds to the total IR intensity associated with the volatiles released by a sample after heating at 20°C/min. By Gram-Schmidt, an insignificant increase in intensity after warm-up is observed before -7 min, followed by a dramatic increase in intensity with maximum ema -11.8 min. The waterfall graph (data not shown) for this sample indicates that volatiles are released after heating after -7 min. (data are shown in Figure 49 using IR spectrum turned on at different times as an example) and volatiles were identified as residual methanol from solvent processing in spray drying and possible acetic acid from HPMC-AS MG.
    Vibrational spectroscopy techniques including IR and Raman were employed to further characterize this ternary dispersion. The overlay of the IR spectra for the x-ray dispersion and amorphous rifaximin is shown in Figure 50. Based on visual inspection, two spectra are very similar. Similar observations can be drawn from comparing the Raman analysis (Figure 51). The sample is composed of collapsing spherical clusters. Sphere particle sizes are not uniform, ranging from slightly larger to much smaller than 10 µm.
    PLM images (data not shown) of solids dispersed in mineral oil were collected, which indicate that the sample is mainly composed of irregularly shaped equant particles approximately 5 to 15 μm in length with some clumps of 20 to 50 µm in length. Particle size analysis (Figure 52) indicates that 50% of the particles are smaller than 8.233 µm and 90% of the particles are smaller than 17.530 µm. Data were acquired on 2% (w/v) Lecithin in Isopar G.
    The solids DVS isotherm is shown in Figure 53. The material shows a loss of 0.13% by weight after equilibration at 5% RH. The solids then gain 11.14% by weight between 5% and 95% RH and show some hysteresis with 10.80% by weight loss after desorption 95% to 5% RH. XRPD analysis of solids recovered after completion of the desorption step showed no evidence of sharp peaks indicative of a crystalline solid (Figure 54). Physical Stability Assessment on Rifaximin Ternary Dispersion
    An assessment of the physical stability of this ternary dispersion of rifaximin is currently underway, by exposing solids to a variety of elevated temperature/relative humidity conditions, including 25°C/60% RH, 40°C/75% RH and 70°C /75% RH for an extended period of time. At designated time intervals, such as 1 week, 3 weeks, 6 weeks and 12 weeks, selected samples were removed from stress conditions for characterization.
    Table 19 summarizes the characterization results for the samples that were tensioned at the condition of 70°C/75% RH one week and 3 weeks, and the sample that was tensioned at the condition of 40°C/75% RH 6 weeks. Table 19. Physical Stability Assessment on Rifaximin Ternary Dispersion
    (a): temperatures are rounded to the nearest degree; ΔCp is rounded to one decimal place. For a sample that has been strained at 70°C/75%RH for one week, the solids are still amorphous on X-ray according to XRPD (Figure 55). A single Tg at approximately 134°C was observed from the apparent step change in the inversion of the heat flux signal in mDSC with the thermal capacity change at 0.4 J/g °C, indicating that the components of each dispersion remained intimately miscible after strain (Figure 56). The non-reversible endotherm was observed at approximately 54°C which is likely due to residual solvent from spray drying and moisture that the materials absorbed during tensioning, which is confirmed by the KF analysis whose sample contains 3.80% by weight of water (KF analysis for ternary dispersion of rifaximin after 70°C/75% RH 1 week; 1.2855 g - R1 = 3.72 and 0.988 g - R1 = 3.87%). The sample is composed of collapsing agglomerates of spheres and the particle sizes of the spheres are not uniform, which is similar to the material as prepared.
    For the sample that was tensioned at 70°C/75%RH for 3 weeks, although the color of the material appears to be darker than the 1 week sample, the characterization results for the 3 week sample are similar to those for one week sample. Solids are also amorphous to x-ray by XRPD (Figure 55) and have a single Tg at approximately 134°C by mDSC (Figure 57). The KF analysis indicates that it contains 3.19% by weight of water (KF analysis for the ternary dispersion of rifaximin after 70°C/75% RH of 3 weeks; 1.2254 g - R1 = 3.45 and 1.1313 g - R1 = 2.93. By SEM (data not shown), the material has similar morphology to the dispersion as prepared and sample under tension for 1 week, which is composed of collapsing bead agglomerates and bead particle sizes are not uniform.
    For the sample that was strained at 40°C/75%RH for 6 weeks, the solids are still amorphous on X-ray according to XRPD (Figure 55). It has a unique Tg of approximately 133°C per mDSC with the change in thermal capacity 0.4 J/g °C (Figure 58). It contains 4.05% by weight water per KF (KF analysis for ternary dispersion of rifaximin after 40°C/75% RH 6 weeks; 1.0947 g - R1 = 3.47 and 1.2030 - R1 = 4.63). By SEM (data not shown), the sample is composed of collapsing sphere agglomerates and the sphere particle sizes are not uniform, which is similar to the material as prepared.
    For the sample that was tensioned at 40°C/75% RH for 12 weeks, the solids are amorphous on x-ray (Figure 55) and have a single Tg of approximately 132°C with the change in thermal capacity 0. 5 J/g °C (Figure 59). It contains 3.37% by weight water per KF (KF analysis for ternary dispersion of rifaximin after 40°C/75% RH 12 weeks; 1.3687 g - R1 = 3.06 and 1.1630 g - R1 = 3.67). SEM analysis (data not shown) indicates that the sample is composed of collapsing agglomerates of spheres and the particle sizes of the spheres are not uniform, which is similar to the material as prepared. Example 3. Rifaximin Solids Dispersion Composition and Procedures
    Rifaximin Ternary Dispersion Ingredients:
    Ternary dispersions of rifaximin (50:50 w/w Rifaximin:HPMC-AS MG with 5.9% by weight Pluronic F-127) were prepared from methanol using spray drying in the closed mode suitable for the organic solvent processing. The ingredients are listed below in Table 20: Table 20. Rifaximin Solid Dispersion Components
    Spray Drying Procedures:
    Ternary dispersions of rifaximin were prepared by spray drying both small scale (~1 g API) and large scale (>34 g API in a single batch).
    For the small scale sample, rifaximin and then methanol were added to a vial. The mixture was stirred at room temperature for ~5 min to provide a clear solution. HPMC-AS MG and Pluronic F-127 were added in succession and the sample was shaken for ~1 h. An orange colored solution was obtained.
    For large scale samples, a solution was prepared at ~40°C. Rifaximin and then methanol were added to a flask and the mixture was stirred at ~40°C for ~5 min until clear. HPMC-AS MG and then Pluronic F-127 were added into the rifaximin solution under stirring at ~40°C. The sample continued to stir for -1.5 h to two hours at this temperature. A dark red solution was obtained. The sample was removed from the hot plate and left to cool.
    The experimental conditions for the preparation of rifaximin ternary solutions are summarized in Table 21 below: Table 21. Experimental conditions for the preparation of rifaximin ternary solutions

    During the spray drying process, both small and large scale ternary solutions of rifaximin were kept at room temperature. Pump % was reduced during the process in an attempt to control the outlet temperature above 40°C. The operational parameters used for processing are presented in Table 22 below. Table 22. Operating Parameters Used for Rifaximin SD Processing
    (a): 50:50 is the approximate ratio of rifaximin to polymer by weight, 5.9% by weight of Pluronic is the weight fraction for the 50:50 rifaximin:HPMC-AS MG dispersion. (b): Flow rates are estimated. The flow rate for 4103-41-01 was measured on the pump at 35%; for 4103-56-01 it was measured at the pump at 65%, while for others it was measured at the pump at 50%.
    Solids recovered after spray drying were dried at 40°C under vacuum for 24 hours and then stored at sub-ambient temperatures over desiccant.
    Spray Drying Process Parameters: • Spray Dryer - PSD 1 • Two Niro Fluid Nozzles • Nozzle Orifice - 1 mm • Inlet Gas Temperature - 125 ± 5°C • Process Gas Flow (mmH20) - 44 • Atomizing gas pressure - 0.7 to 1 bar • Feed rate - 4.7 kg/h • Outlet temperature - 55 ± 3°C • Solution temperature - 36°C • Vacuum drying after drying by spraying at 40°C for 48 h Example 4.
    Exemplary formulations for the micronized dispersion, API, amorphous, solid and micronized capsules are below in Table 23. These capsules were used in the dog study of Example 5. Table 23. Composition of Capsule Formulation (Disper Capsules are Solid (SD) ))
    Table 24. Manufacture of Rifaximin/HPMC-AS/Pluronic 275 mg Capsules
    Mixing/Encapsulation Procedure:
    To form the capsules croscarmellose sodium was added to the rifaximin SD dispersion bag and the bag mixed for 1 minute, and then the material was added to the V-blender and mixed for 10 minutes at 24 rpm.
    The material was then unloaded into a stainless steel autoclave and the height of the material in the autoclave recorded. The empty capsules 10 were marked for weight using an analytical balance, then the capsules were loaded by pushing down on the bed of material. The weight is adjusted to within + or - 5% of the target filled weight of 647.5 mg (acceptable load range 615.13 to 679.88 mg).
    Figures 61 to 63 show solid dispersion 15 capsules of rifaximin (SD) in various buffers; with and without SDS; and compared to amorphous rifaximin. Figure 61 shows the results of dissolution studies of rifaximin SD capsules in acid phase: 0.1 N HCI with variable exposure times in a buffer containing 0.45% SDS at pH 6.8. Figure 62 shows the results of dissolution studies of rifaximin SD capsules in the acid phase for 2 hours buffered at pH 6.8 with and without SDS. Figure 63 shows the results of dissolution studies of rifaximin SD capsules in the acid phase in a phosphate buffer at pH 6.8 with 0.45% SDS compared to amorphous rifaximin. As shown in Figures 61 to 63 rifaximin SD close to 100% dissolution is obtained in 0.45% SDS and the SD formulation dissolves more slowly than amorphous rifaximin. Example 5. Pharmacokinetic (PK) studies of solid dispersion in capsules
    Presented here are pharmacokinetic (PK) studies in dogs comparing the various forms of rifaximin. PK after administration of rifaximin API in the capsule, micronized API in the capsule, nanocrystal API in the capsule (containing surfactant), amorphous in the capsule, and solid dispersion (SD) in the capsule were tested.
    In the SD dosage form, the polymer used was HPMC-AS at a drug to polymer ratio of 50:50. The formulation also comprises pluronic F127 and croscarmellose sodium (see Example 4).
    A brief study design: Male beagle dogs (N = 6, approximately 10 kg) received 2200 mg of rifaximin in the dosage forms described above as a single dose (capsules, 275 mg, 8 capsules given in rapid succession) in a crossover scheme with weekly washout between phases. Blood was collected at timed intervals for 24 hours after dosing administration, and plasma was collected for LC-MS/MS analysis. Average concentrations are shown in Figure 60.
    Table 25 shows the PK parameters. From the table it can be seen that the systemic exposure of the solid dispersion formulation is greater than that of the amorphous or crystalline form (API) of rifaximin. Table 25. PK Parameters of API, Amorphous and Solid Dispersion in Dogs

    API exposures were low, in line with what was previously observed for rifaximin. In contrast, mean exposures (AllCinf) following administration of amorphous and SD rifaximin were substantially higher, with exposures greater than ~40 and ~100 times, respectively, compared to API. Variability was high in all three dose groups. In general, the forms of all three profiles were similar, suggesting effects of dosage forms on bioavailability with no effects on release or volume of distribution. Example 6. Human Clinical Studies
    Rifaximin SDD with 10% CS formulation has been used in human clinical studies. Figure 65 shows the kinetic solubility of rifaximin SD granules 10% by weight CS FaSSIF or 10% by weight CS FeS-SIF (a) and the dissolution profiles of the SDD 10% CS tablet in 0.2% SLS at pH 4 .5, 5.5 and 7.4. As shown in Figure 65, rifaximin SDD 100% or nearly 100%, dissolution is achieved at 0.2% SLS, pH 4.5, 5.5 and 7.4. Figure 66 shows that release can be delayed up to two hours and extended up to three hours. Example 7. Effects of median pH on dissolution
    Figures 67 to 70 show the effects of median pH on the dissolution of the rifaximin SDD tablet at various CS levels: 0%, 2.5%, 5% and 10% CS. Figures 67 and 68 show the dissolution profiles of the SDD tablet with 0%, 2.5%, 5% or 10% CS, with 0.2% SDS in two hours pH 2.0, pH 4.5, 0 .2% SDS, pH 5.5, or 0.2% SDS, pH 7.4. Figures 69 and 70 show the dissolution profiles of the 2.5% CS, 0% CS, 10% CS and 5% CS SDD tablet in 0.2% SLS, pH 4.5, 0.2% SLS, pH 5.5 and 0.2% SLS, pH 7.4. Figure 71 shows CS release mechanism. Example 8.
    Described herein is the preparation and characterization of quaternary dispersions of rifaximin with antioxidants. The antioxidants used were butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT) and propyl gallate (PG). Sample Preparation and Characterization
    Three quaternary samples of rifaximin were prepared by spray drying methanol. The spray drying parameters are summarized in Table 26. Table 2 Parameters for 5 Samples Prepared by Spray Drying. Table 26
    (a): Flow rates are calculated based on the initial pump % of 45%. Table 27 Characterization of Quaternary Rifaximin Samples

    A small sub-batch of each of the spray dried materials was visually inspected by PLM and characterized by XRPD and mDSC. The characterization results are summarized in Table 27.
    The prepared materials are amorphous to x-ray, as shown in Figure 72 overlaying XRPD patterns, which match their PLM observations.
    In mDSC, each of the materials has a unique apparent Tg in the heat flux signal reversal at approximately 133°C (Figure 73, with 0.063% by weight BHA), 133°C (Figure 74, with 0.063% by weight of BHT) and 134°C (Figure 75, with 0.094% by weight of PG), which is consistent with the Tg of the spray-dried rifaximin ternary dispersion 47.2:47.2:5.6 w/w/ p/rifaximin/HPMC-AS MG/Pluronic F-127 (135 or 136°C). Example 9: Solid Dispersions of Rifaximin
    This example presents exemplary microgranules of rifaximin and pharmaceutical compositions comprising them.
    Spray dried dispersion (SDD), solid dispersion, solid amorphous dispersion are used interchangeably herein to refer to rifaximin formulations.
    The full report of the components and the quantitative composition of the Rifaximin Solid Dispersion Formulation (Intermediate) is provided in Table 28 Table 28: Rifaximin Solid Dispersion Formulation Composition

    Rifaximin solid dispersion IR capsule composition. Table 29: Rifaximin Solid Dispersion IR Capsule Composition
    Table 30

    Manufacturing Process for Rifaximin Solid Dispersion IR Capsules
    The manufacturing process for rifaximin solid dispersion IR capsules is given in Table 31. Table 31: Manufacturing of Rifaximin Solid Dispersion Microgranules in IR Capsules Component Process

    Exemplary spray drying processes are shown in Table 32. Table 32: Spray Drying Process: • Spray Dryer - PSD 1 • Two Fluid Niro Nozzles • Nozzle Orifice - 1 mm • Inlet Gas Temperature - 125 ± 3°C • Process gas flow (mmH20) - 44 • Atomizing gas pressure - 1 bar • Feed rate - 4.7 kg/h • Outlet temperature - 55 ± 3°C • Solution temperature - 36°C • Vacuum drying after spray drying at 40°C for 48 h
    Example 10: Characterization of Medicine Product Samples Containing Rifaximin Solid Dispersion
    Described here are the dissolution data for the solid dispersion rifaximin roller compact materials with varying levels (0, 2.5%, 5% and 10%) of croscarmellose sodium.
    Three roller compacted materials of solid amorphous dispersion rifaximin with varying levels (0, 2.5%, 5%) of croscarmellose sodium were tested for dissolution. The results are compared with the dissolution of rifaximin granules with 10 10% croscarmellose sodium. Dissolution Studies with the USP Paddle Method
    Dissolution tests were performed on roller-compacted materials as received from solid dispersion rifaximin with 0.2.5% by weight, and 5% by weight of croscarmellose sodium. Solid powders were directly added in pH 6.5 FaSSIF buffer with gentle agitation of the media (paddle shaker at 50 rpm) at 37°C for 24 hours.
    At designated times of 5, 10, 20, 30, 60, 90, 120, 240 and 1440 minutes, aliquots were removed from each of the samples. Analysis of the data indicates that an increase in rifaximin concentration is evident with an increase in the level of croscarmellose sodium in the materials, particularly in the early stage of dissolution. After 24 hours, the rifaximin concentration of granules containing 5% by weight of croscarmellose sodium is similar to granules with 10% by weight of croscarmellose sodium. Example 11: Characterization of Rifaximin Solid Dispersion Powder 42.48% w/w
    Described here is the characterization of Rifaximin Solid Dispersion Powder 42.48% w/w. Dissolution testing was also performed on material at pH 6.5 with FaSSIF at 37°C.
    A ternary dispersion sample of rifaximin was characterized by XRPD, mDSC, TG-IR, SEM and KF.
    X-ray powder diffraction (XRPD) analysis using a method for Rifaximin Solid Dispersion Powder 42.48% w/w was conducted. The XRPD pattern by visual inspection is amorphous to x-ray without sharp peaks (Figure 76). By mDSC a single apparent Tg is observed from the step change in the inversion of the heat flux signal at approximately 134°C, with a thermal capacity change at the Tg of approximately 0.36 J/g*°C.
    Thermogravimetric analysis coupled with infrared spectroscopy (TG-IR) was performed to analyze the volatiles generated after heating. The total weight loss of the sample was approximately 0.4% by weight at 100°C, and a dramatic change in slope occurs at approximately 190°C, which is likely due to decomposition. The Gram-Schmidt plot corresponds to the global IR intensity associated with the volatiles released by a sample after heating to °C/min. Gram-Schmidt indicates that volatiles are released upon heating after ~8 mm, and volatiles were identified as residual methanol from spray drying processing solvent and possible acetic acid from HPMC-AS MG.
    KF analysis indicates that the material contains 1.07% by weight of water [(1.00 + 1.13)/2 = 1.07%]. Example 12: Method for ternary dispersion of rifaximin by spray drying (50:50 w/w rifaximin:HPMC-AS MG with 5.9% by weight of Pluronic F-127).
    Provided herein are procedures for spray drying the ternary dispersion of rifaximin (50:50 w/w rifaximin:HPMC-AS MG with 5.9% by weight Pluronic F-127).
    Ternary dispersions of rifaximin (50:50 w/w Rifaximin:HPMC-AS MG with 5.9% by weight Pluronic F-127) were prepared from methanol using Büchi B-290 Mini Spray Dryer in closed mode Suitable for processing organic solvents. The ingredients are listed in Table 33 below: Table 33

    The ternary dispersions of rifaximin were prepared by spray drying both small scale (~ 1 g API) and large scale (> 34 g API in a single batch).
    For a small scale sample, rifaximin and then methanol were added into a clean bottle. The mixture was stirred at room temperature for ~5 min to give a clear solution. HPMC-AS MC and Pluronic F-127 were added in succession and the sample was shaken for ~1 h. An orange solution was obtained.
    For a large scale sample, the solution was prepared at ~40°C. Rifaximin and then methanol were added to a clean flask and the mixture was stirred at ~40°C for ~5 minutes until clear. HPMC-AS MG, and then Pluronic F-127 were added into the rifaximin solution under stirring ~40°C. The sample continued to stir for —1.5 h to 2 h at this temperature. A dark red solution was obtained. The sample was removed from the hot plate and left at room temperature to cool.
    The experimental conditions for the preparation of rifaximin ternary solutions are summarized in Table 34 below: Table 34

    During the spray drying process, both small and large scale ternary solutions of rifaximin were kept at room temperature. Pump % was reduced during the process in an attempt to control the outlet temperature above 40°C. The operating parameters used for processing are shown in Table 35 below. Table 35:
    (a): 50:50 is the approximate ratio of rifaximin to polymer, by weight, 5.9% by weight of Pluronic is the 50:50 weight fraction of rifaximin:HPMC-AS MG dispersion. (b): flow rates are estimated. The flow rate for 4103-41-01 was measured on the pump at 35%; for 4103-56-01 it was measured at the pump at 65%, while for others it was measured at the pump at 50%.
    The solids recovered after spray drying were dried at 40°C under vacuum for 24 hours and then stored in the sub-environment (refrigerator) with desiccant. Example 13. Non-clinical data - comparison of form/formulation and variable doses in dogs.
    Described here are non-clinical data, form/formulation comparison in dogs and variable SDD dose in dogs. Figure 77 indicates the results of two studies conducted to characterize the pharmacokinetics of rifaximin following administration of varying forms and formulations after a single oral dose. Blood samples were collected at time intervals during the 24 h after single dose administration (total dose 2200 mg in each case) and processed in plasma for analysis of rifaximin concentrations. PK parameters were estimated by non-compartmental methods. The results are shown in Figure 77. Of the forms/formulations shown, the spray-dried dispersion showed that the highest exposure, and therefore the greatest bioavailability, resulted from the administration of the SDD formulation (administered in doses as SDD powder in gelatin capsules). In order to decrease exposure between dosage forms in the gelatin capsule formulation, SDD > a-morph >iota > micronized >eta >current crystalline API. Lower in systemic exposure than all of these are the micronised suspension formulation (powder reconstituted into oral suspension), and the current 550 mg tablet Xifaxan. Table 36 below shows the PK parameters for dog shapes. Table 36

    Figure 78 shows the results of dose escalation for dog, where dogs received single doses of the SDD formulation in capsules, in doses from 150 mg to 2200 mg. The results indicate an essentially linear dose escalation (increases in exposure that are approximately proportional to the increase in dose) of up to 550 mg, followed by a greater than proportional increase at 1100 mg and 2200 mg. This is quite unusual in the linear range where the current crystalline form of rifaximin does not increase the dose, generally the exposure does not increase substantially with increasing doses. The increase greater than the proportional dose over the increasing dose is also notable and suggests that, at the higher doses, rifaximin is saturating the intestinal P-glycoprotein transport which would otherwise limit systemic absorption, thus allowing for increased absorption. Example 14. Human Studies
    Clinical studies performed on ten male human subjects are described herein. Figure 79 shows the quotient study design for rifaximin SDD dose escalation. Figure 80 depicts the regional scaling/absorption study, dose/dose scaling selection. Figures 81 and 82 show representative individual data from an exemplary dose escalation study. Mean data (linear scale and log scale) are shown in Figures 83 and 84, respectively. Average profiles, log scale. The terminal phases are parallel in the release mechanisms. A summary of rifaximin SDD dose escalation is shown indicating that there is likely to be no metabolic or systemic saturation Figure 85. To summarize, there are approximately proportional increases in exposure dose (Cmax and AUC) with increases in dose, as shown by multiples Cmax columns and multiple AUC columns. Tmax is not delayed by dose increases, further indicating an early absorption window (supported by regional absorption data). The percentage of dose in urine is notable in that it is low, approximately 0.2% or less of the dose excreted over 24 h. This result is surprising as this is very low despite significant increases in systemic exposure compared to the crystalline formulation. Taken together, the results indicate a considerably increased solubility that presumably leads to an increase in local soluble rifaximin Zlumenal, with accompanying increases in systemic exposure, but no significant increases in urinary excretion that are reflective of the percentage of absorbed dose. of rifaximin.
    Dose/dosage form comparisons are shown in Figures 86 and 87. The tables compare SDD at increasing doses for the current crystalline formulation in terms of systemic PK. As seen in Figure 87, compared to the PK of rifaximin from the current formulation, the SDD formulation at the same dose shows an approximate 6.4-fold increase in Cmax θ an approximate 8.9-fold increase in AUC. However, these exposures are lower than those seen in any individual with liver failure with the current tablet formulation. Example 15. Exemplary Tablet Formulations
    In accordance with certain exemplary embodiments, microgranules, blends and tablets are formulated as shown in Table 37, below. Table 37 Rifaximin SDD granules
    Mixture of granules mg/Tab mg/Tab mg/Tab mg/Tab
    Rifaximin Tablet Composition
    权利要求:
    Claims (41)
    [0001]
    1. Solid dispersion form of rifaximin, characterized in that it comprises rifazimine and one or more selected polymers of hydroxypropyl methylcellulose phthalate (HPMC-P), hydroxypropyl methylcellulose acetate succinate (HPMC-AS) and a polymethacrylate (Eudragit® L100-55), wherein the weight ratio of rifaximin:polymer is in the range of 10:90 to 90:10.
    [0002]
    2. Solid dispersion form of rifaximin according to claim 1, characterized in that the HPMC-AS comprises one or more grades of HG or MG.
    [0003]
    3. Solid dispersion form of rifaximin, according to claim 2, characterized in that the HPMC-P comprises grade 55.
    [0004]
    4. Form of solid dispersion of rifaximin, according to claim 3, characterized in that it further comprises a poloxamer.
    [0005]
    5. Solid dispersion form of rifaximin according to claim 4, characterized in that the poloxamer comprises poloxamer 407 or Pluronic F-127.
    [0006]
    6. Solid dispersion form of rifaximin according to claim 1, characterized in that it further comprises polyvinylpyrrolidone (PVP) grade K-90.
    [0007]
    7. Solid dispersion form of rifaximin according to claim 1, characterized in that the weight ratio of rifaximin: polymer is in the range of 15:85 to 85:15.
    [0008]
    8. Form of solid dispersion of rifaximin according to claim 7, characterized in that the weight ratio of rifaximin: polymer is in the range of 25:75 to 75:25.
    [0009]
    9. Solid dispersion form of rifaximin according to claim 8, characterized in that the weight ratio of rifaximin: polymer is in the range of 40:60 to 60:40.
    [0010]
    10. Form of solid dispersion of rifaximin according to claim 1, characterized in that the weight ratio of rifaximin: polymer is 50:50.
    [0011]
    11. Shape according to claim 1, characterized in that the shape has the appearance of a single glass transition temperature (Tg).
    [0012]
    12. Form according to claim 1, characterized in that a Tg of a form increases with an increased concentration of rifaximin.
    [0013]
    13. Form according to claim 1, characterized in that the solid dispersion is subjected to tension at 70°C/75% RH for 1 week, the solids are still amorphous to x-ray according to XRPD.
    [0014]
    14. Form according to claim 1, characterized in that the solid dispersion is subjected to tension at 70°C/75% RH for 3 weeks, the solids are still amorphous to x-ray according to XRPD.
    [0015]
    15. Form according to claim 1, characterized in that the solid dispersion is subjected to tension at 70°C / 75% RH for 6 weeks, the solids are still amorphous to x-ray according to XRPD.
    [0016]
    16. Form according to claim 1, characterized in that the solid dispersion is subjected to tension at 70°C / 75% RH for 12 weeks, the solids are still amorphous to x-ray according to XRPD.
    [0017]
    17. Microgranule, characterized in that it comprises a solid dispersion of rifaximin as defined in any one of claims 1 to 16.
    [0018]
    18. Microgranule according to claim 17, characterized in that it further comprises an intragranular release control agent.
    [0019]
    19. Microgranule according to claim 18, characterized in that the intragranular release control agent comprises a pharmaceutically acceptable excipient and/or disintegrant.
    [0020]
    20. Microgranule according to claim 19, characterized in that the pharmaceutically acceptable disintegrant is one selected from the group consisting of crosprovidone, sodium starch glycolate, corn starch, microcrystalline cellulose, cellulosic derivatives, sodium bicarbonate and alginate sodium.
    [0021]
    21. Microgranule according to claim 17, characterized in that it further comprises a surfactant.
    [0022]
    22. Microgranule according to claim 17, characterized in that it further comprises an antioxidant.
    [0023]
    23. Pharmaceutical composition, characterized in that it comprises the microgranule as defined in any one of claims 17 to 22.
    [0024]
    24. Pharmaceutical composition according to claim 23, characterized in that it further comprises one or more pharmaceutically acceptable excipients.
    [0025]
    25. Pharmaceutical composition according to claim 23, characterized in that the composition is in the form of a tablet or capsule.
    [0026]
    26. Pharmaceutical composition according to claim 25, characterized in that it comprises a disintegrant.
    [0027]
    27. Pharmaceutical composition, characterized in that it comprises the solid dispersion of rifaximin as defined in claim 1 and at least one pharmaceutically acceptable excipient.
    [0028]
    28. Pharmaceutical composition according to claim 27, characterized in that it comprises a solid dispersion of rifaximin, a polymer, a surfactant, and a release control agent.
    [0029]
    29. Pharmaceutical composition according to claim 28, characterized in that it comprises a solid dispersion of rifaximin, HPMC-AS, poloxamer and croscarmellose Na (CS).
    [0030]
    30. Pharmaceutical composition according to claim 28, characterized in that the pharmaceutical compositions are tablets or pills.
    [0031]
    31. Pharmaceutical composition according to claim 28, characterized in that it further comprises fillers, glidants and lubricants.
    [0032]
    32. Pharmaceutical composition according to any one of claims 29 to 31, characterized in that it comprises the proportion of components according to the table below:
    [0033]
    33. Process for the production of a solid dispersion of rifaximin, characterized in that it comprises: the production of a slurry of methanol, rifaximin, HPMC-AS MG and poloxamer 407; spray drying the slurry.
    [0034]
    34. Process for the production of a solid dispersion of rifaximin, characterized in that it comprises spray drying of rifaximin and Eudragit L100-55 in a weight ratio of 25:75, 50:50 or 75:25.
    [0035]
    35. Process for the production of a solid dispersion of rifaximin, characterized in that it comprises spray drying of rifaximin and HPMC-ASS MG in a 50:50 weight ratio or spray drying of rifaximin and HPMC-P in a 25:75 weight ratio.
    [0036]
    36. Pharmaceutical composition according to claim 27, characterized in that it is for use in the prevention or treatment of bacterial infection.
    [0037]
    37. Pharmaceutical composition according to claim 27, characterized in that it is for use in the prevention or treatment of disorders related to the bowel.
    [0038]
    38. Pharmaceutical composition according to claim 37, characterized in that the bowel-related disorder includes irritable bowel syndrome, diarrhea, diarrhea associated with microbes, diarrhea associated with Clostridium difficile, travelers' diarrhea, small bowel bacterial growth, Crohn's disease, diverticular disease, chronic pancreatitis, pancreatic insufficiency, enteritis, colitis, hepatic encephalopathy, minimal hepatic encephalopathy, or pouchitis.
    [0039]
    39. Pharmaceutical composition according to claim 37, characterized in that the bowel-related disorder is hepatic encephalopathy.
    [0040]
    40. Pharmaceutical composition according to claim 37, characterized in that the bowel-related disorder is irritable bowel syndrome.
    [0041]
    41. Pharmaceutical composition according to claim 37, characterized in that the bowel-related disorder is Crohn's disease.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112013000802B1|2021-08-31|Solid dispersion form of rifaximin, microgranule comprising said form, pharmaceutical composition comprising said microgranule and processes for producing a solid dispersion of rifaximin
    CN102015725B|2014-10-22|Forms of rifaximin and uses thereof
    ES2464367T3|2014-06-02|Pharmaceutical Composition for a Hepatitis C Virus Protease Inhibitor
    ES2633766T3|2017-09-25|Bile acid recycling inhibitors for the treatment of pediatric cholestatic liver diseases
    Moes et al.2011|Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel |
    JP2016094416A|2016-05-26|Forms of rifaximin and uses thereof
    CN103827122A|2014-05-28|Forms of rifaximin and uses thereof
    EP2776014A2|2014-09-17|Melatonin-based solutions and powders for their preparation
    ES2538359T3|2015-06-19|Methods for administering an active 1,2,4-oxadiazole orally for nonsense mutation suppression therapy
    TWI500431B|2015-09-21|Oral dosage forms of bendamustine
    BRPI0615195A2|2011-05-10|pharmaceutical preparation, packaging, use of balsalazide, and method for making a capsule and for testing dissolution of balsalazide capsules
    ES2727594T3|2019-10-17|Sustained-release granules containing tacrolimus as active ingredient
    US20170087134A1|2017-03-30|Formulations of rifaximin and uses thereof
    CZ200484A3|2005-01-12|Lyophilized preparation containing olanzapin
    CN104352554B|2018-09-25|A kind of compound Cefquinome antibacterials
    CN102525908B|2013-04-17|Carbazochrome sodium sulfonate pharmaceutical composition and preparation method thereof
    US20200138742A1|2020-05-07|Ophthalmic composition containing clathrated antioxidant substance, and use thereof
    CN105663031A|2016-06-15|Cetirizine hydrochloride gel as well as preparation method and application thereof
    NZ613569B2|2015-11-03|Forms of rifaximin and uses thereof
    同族专利:
    公开号 | 公开日
    LT2593463T|2020-08-25|
    US20170333562A1|2017-11-23|
    DK2593463T3|2020-08-10|
    ZA201300193B|2019-07-31|
    TN2012000611A1|2014-04-01|
    EP3750526A1|2020-12-16|
    HUE049986T2|2020-11-30|
    NZ605232A|2015-09-25|
    JP2013532633A|2013-08-19|
    BR112013000802A2|2016-05-24|
    PT2593463T|2020-09-17|
    CA2804635C|2019-09-10|
    KR101887004B1|2018-08-09|
    SG10201505484RA|2015-09-29|
    ES2801678T3|2021-01-12|
    MX2013000522A|2013-05-01|
    JP5943915B2|2016-07-05|
    MX345697B|2017-02-13|
    CN103228662B|2016-08-10|
    AU2011279261A1|2013-01-17|
    CR20130033A|2013-04-29|
    EA033370B1|2019-10-31|
    MY165086A|2018-02-28|
    WO2012009387A1|2012-01-19|
    EP2593463A1|2013-05-22|
    CA2804635A1|2012-01-19|
    PL2593463T3|2020-11-02|
    EA201370018A1|2013-09-30|
    KR20130098300A|2013-09-04|
    EP2593463B1|2020-05-06|
    US20120077835A1|2012-03-29|
    WO2012009388A1|2012-01-19|
    SG186981A1|2013-02-28|
    AU2011279261B2|2016-03-31|
    SI2593463T1|2020-10-30|
    EP2593463A4|2014-04-23|
    US20200397904A1|2020-12-24|
    US20150133482A1|2015-05-14|
    IL223725A|2020-03-31|
    CN103228662A|2013-07-31|
    US9737610B2|2017-08-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    IT1154655B|1980-05-22|1987-01-21|Alfa Farmaceutici Spa|IMIDAZO-RIFAMYCIN DERIVATIVES METHODS FOR THEIR PREPARATION AND USE AS AN ANTIBACTERIAL ACTION SUBSTANCE|
    IT1199374B|1984-05-15|1988-12-30|Alfa Farmaceutici Spa|PROCESS FOR THE PREPARATION OF PIRIDO-IMIDAZO-RIFAMICINE|
    IT1320176B1|2000-12-22|2003-11-26|Nicox Sa|SOLID DISPERSIONS OF NITRATED ACTIVE INGREDIENTS.|
    ES2284871T3|2001-06-22|2007-11-16|Pfizer Products Inc.|PHARMACEUTICAL COMPOSITIONS CONTAINING A SOLID DISPERSION OF LITTLE SOLUBLE PHARMACO AND A SOLUBILITY POTENTIATING POLYMER.|
    ITMI20032144A1|2003-11-07|2005-05-08|Alfa Wassermann Spa|REFLEXIMINE POLIMORPHIC FORMS, PROCESSES TO OBTAIN THEM AND|
    EP1701704A2|2003-12-31|2006-09-20|Pfizer Products Inc.|Solid compositions of low-solubility drugs and poloxamers|
    US20060058358A1|2004-08-27|2006-03-16|Jacques Dumas|Pharmaceutical compositions for the treatment of hyper-proliferative disorders|
    ES2522895T3|2005-03-03|2014-11-19|Alfa Wassermann S.P.A.|New polymorphic forms of rifaximin, procedures for their production and use in medicinal preparations|
    ITBO20050123A1|2005-03-07|2005-06-06|Alfa Wassermann Spa|GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA|
    US20080095754A1|2006-10-18|2008-04-24|Burke Susan E|Ophthalmic compositions comprising diglycine|
    PL2011486T5|2007-07-06|2016-09-30|Lupin Ltd|Pharmaceutical compositions of rifaximin|
    US8383151B2|2007-07-06|2013-02-26|Lupin Limited|Pharmaceutical compositions of rifaximin|
    KR100903618B1|2007-10-30|2009-06-18|삼성에스디아이 주식회사|Plasma display panel|
    US8486956B2|2008-02-25|2013-07-16|Salix Pharmaceuticals, Ltd|Forms of rifaximin and uses thereof|
    MX2010009389A|2008-02-25|2010-11-22|Salix Pharmaceuticals Ltd|Forms of rifaximin and uses thereof.|
    EP2105130A1|2008-03-25|2009-09-30|Ratiopharm GmbH|Pharmaceutical formula and method for its production|
    WO2010067072A1|2008-12-10|2010-06-17|Cipla Limited|Rifaximin complexes|
    KR101972354B1|2009-10-27|2019-04-25|루핀 리미티드|Solid dispersion of rifaximin|
    WO2011061748A1|2009-11-19|2011-05-26|Strides Arcolab Limited|Rifaximin premix|
    EA021570B1|2010-03-10|2015-07-30|Эббви Бахамаз Лтд.|Solid compositions for the treatment of hcv infections |ES2522895T3|2005-03-03|2014-11-19|Alfa Wassermann S.P.A.|New polymorphic forms of rifaximin, procedures for their production and use in medicinal preparations|
    ITBO20050123A1|2005-03-07|2005-06-06|Alfa Wassermann Spa|GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA|
    US9018684B2|2009-11-23|2015-04-28|California Institute Of Technology|Chemical sensing and/or measuring devices and methods|
    IT1398550B1|2010-03-05|2013-03-01|Alfa Wassermann Spa|RIFAXIMINA COMPREHENSIVE FORMULATIONS USEFUL TO OBTAIN A PROLONGED EFFECT IN TIME|
    ITBO20110461A1|2011-07-29|2013-01-30|Alfa Wassermann Spa|PHARMACEUTICAL COMPOSITIONS INCLUDING RIFAXIMINA, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS.|
    AU2012332211B2|2011-11-02|2016-11-24|Salix Pharmaceuticals, Ltd.|Methods for treating irritable bowel syndromeand infections|
    AU2013212008A1|2012-01-25|2014-07-10|Alfa Wassermann S.P.A.|Rifaximin derivative and uses thereof|
    ITBO20120368A1|2012-07-06|2014-01-07|Alfa Wassermann Spa|COMPOSITIONS INCLUDING RIFAXIMINA AND AMINO ACIDS, RIFAXIMINE CRYSTALS DERIVING FROM SUCH COMPOSITIONS AND THEIR USE.|
    EP2757135B1|2013-01-18|2017-11-29|3M Innovative Properties Company|Method of bonding parts to a vehicle by an acrylic foam tape|
    WO2015069305A1|2013-11-08|2015-05-14|Tyrx, Inc.|Antimicrobial compositions and methods for preventing infection in surgical incision sites|
    CA2947962A1|2014-05-04|2015-11-12|Salix Pharmaceuticals, Inc.|Ibs microbiota and uses thereof|
    ES2742106T3|2014-05-12|2020-02-13|Alfasigma Spa|New form of solvated rifaximin crystal, production, compositions and uses thereof|
    CN110072525A|2016-09-30|2019-07-30|萨利克斯药品公司|The solid dispersion form of rifaximin|
    CN110621305A|2017-07-24|2019-12-27|爱科思华制药研发有限责任公司|High drug loading pharmaceutical composition|
    CN109453166B|2018-10-16|2021-03-12|丹诺医药(苏州）有限公司|Solid dispersion of rifamycin-quinolizinone coupled molecules and application thereof|
    CN109453165B|2018-10-16|2021-02-05|丹诺医药(苏州）有限公司|Solid dispersion of rifamycin-nitroimidazole coupled molecule and application thereof|
    WO2020198136A1|2019-03-22|2020-10-01|New York Medical College|Use of rifaximin on circulating aged neutrophils in sickle cell disease|
    WO2021058656A1|2019-09-24|2021-04-01|Bausch Health Ireland Limited|Rifaximin liquid formulations|
    WO2021209459A1|2020-04-13|2021-10-21|Bausch Health Ireland Limited|Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease|
    WO2021260211A1|2020-06-26|2021-12-30|Bausch Health Ireland Limited|Targeted release rifaximin compositions|
    法律状态:
    2018-04-10| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-06-30| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
    2020-09-29| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|
    2020-12-29| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-04-06| B06A| Patent application procedure suspended [chapter 6.1 patent gazette]|
    2021-07-13| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-08-31| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/07/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |
    优先权:
    申请号 | 申请日 | 专利标题
    US36360910P| true| 2010-07-12|2010-07-12|
    US61/363,609|2010-07-12|
    US41905610P| true| 2010-12-02|2010-12-02|
    US61/419,056|2010-12-02|
    PCT/US2011/043769|WO2012009388A1|2010-07-12|2011-07-12|Formulations of rifaximin and uses thereof|
    [返回顶部]